1. AbCellera (NASDAQ:ABCL) will announce its second quarter 2021 financial results on Thursday, August 12, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

    The live webcast of the earnings conference call will be available through a link that will be posted on AbCellera's Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to…

    AbCellera (NASDAQ:ABCL) will announce its second quarter 2021 financial results on Thursday, August 12, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

    The live webcast of the earnings conference call will be available through a link that will be posted on AbCellera's Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more info, visit www.abcellera.com.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  2. AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today that Neil Berkley has been appointed as Chief Business Officer (CBO). Mr. Berkley's role will include leading the strategy and continued growth of AbCellera's partnership business, which currently includes a diverse portfolio of more than 100 programs with drug developers of all sizes.

    "Neil brings a wealth of business development experience that will be instrumental as we continue to execute our long-term strategy of using partnerships to accelerate the development of antibody therapeutics for a wide array of diseases," said Carl Hansen, Ph.D., CEO of AbCellera. "We are excited to welcome Neil to the team…

    AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today that Neil Berkley has been appointed as Chief Business Officer (CBO). Mr. Berkley's role will include leading the strategy and continued growth of AbCellera's partnership business, which currently includes a diverse portfolio of more than 100 programs with drug developers of all sizes.

    "Neil brings a wealth of business development experience that will be instrumental as we continue to execute our long-term strategy of using partnerships to accelerate the development of antibody therapeutics for a wide array of diseases," said Carl Hansen, Ph.D., CEO of AbCellera. "We are excited to welcome Neil to the team and look forward to his leadership in expanding our commercial reach across the globe."

    Mr. Berkley has more than 20 years of strategic planning and corporate and business development experience across a wide range of transactions and therapeutic indications. He joins AbCellera from Halozyme Therapeutics, where he served as Vice President, Head of Business Development. Mr. Berkley has held leadership roles at Axerovision, COI Pharmaceuticals, Acadia Pharmaceuticals, Cadence Pharmaceuticals, and GSK. He also cofounded Mpex Pharmaceuticals, which was acquired by Aptalis, and Vaxiion, a clinical stage bladder cancer company.

    "AbCellera has established itself both as a technology leader in antibody-based drug discovery and a true innovator in the business of therapeutic development," said Mr. Berkley. "I am excited to join AbCellera's leadership team and look forward to forging partnerships across the industry that have the potential to accelerate the delivery of new treatments for people in need."

    Mr. Berkley earned a B.S. in molecular biology from UC San Diego, an M.S. in cellular and molecular biology, and an MBA from San Diego State University.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit ww.abcellera.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  3. 130,000-square-foot Vancouver facility aims to accelerate the development of antibody-based therapies for an array of medical conditions.

    AbCellera (NASDAQ:ABCL) today announced it has secured a site in Vancouver for the construction of a Good Manufacturing Practices (GMP) manufacturing facility for the production of therapeutic antibodies, which will be the first of its kind in Canada. The 130,000-square-foot facility will expand AbCellera's capabilities in bringing new antibody therapies to clinical trials, supporting Canada's efforts to respond quickly and effectively to future pandemics and providing AbCellera's partners with a full solution for accelerating their programs from a drug target to the submission of an Investigational New…

    130,000-square-foot Vancouver facility aims to accelerate the development of antibody-based therapies for an array of medical conditions.

    AbCellera (NASDAQ:ABCL) today announced it has secured a site in Vancouver for the construction of a Good Manufacturing Practices (GMP) manufacturing facility for the production of therapeutic antibodies, which will be the first of its kind in Canada. The 130,000-square-foot facility will expand AbCellera's capabilities in bringing new antibody therapies to clinical trials, supporting Canada's efforts to respond quickly and effectively to future pandemics and providing AbCellera's partners with a full solution for accelerating their programs from a drug target to the submission of an Investigational New Drug (IND) application.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005425/en/

    Rendering of AbCellera's GMP Facility at 900-Block Evans Avenue. Images provided by Chernoff Thompson Architects

    Rendering of AbCellera's GMP Facility at 900-Block Evans Avenue. Images provided by Chernoff Thompson Architects

    "We envision AbCellera as a premier destination for the brightest and most creative minds, for people who seek challenges and who want to work at the leading edge," said Murray McCutcheon, Ph.D., Vice President of Corporate Development at AbCellera. "Our recently announced headquarters and new GMP facility will empower entirely new capabilities and jobs in Canada that we believe will make our communities stronger, bring treatments to patients sooner, and leave a legacy of innovation."

    This announcement follows AbCellera's April groundbreaking on a new global headquarters in Vancouver. The 380,000-square-foot headquarters on 4th Avenue between Columbia and Manitoba Streets will be within walking distance of the new GMP manufacturing facility. The new GMP facility will be built on what is currently a vacant two-acre site, and the planned building will house laboratory, office, GMP protein biologic manufacturing, and warehouse space. Design efforts are already underway and groundbreaking is scheduled for later this year.

    In parallel with the construction of the new facility, AbCellera is also building up an internal Chemistry Manufacturing and Controls (CMC) development organization – the team of scientists and engineers responsible for developing the manufacturing processes for antibody therapeutics. CMC and GMP manufacturing capabilities will extend AbCellera's competencies and, when combined with AbCellera's world-leading technology stack for antibody discovery, will enable AbCellera to support partners to move rapidly and seamlessly from discovery to the clinic.

    "AbCellera has already redefined the speed of antibody drug discovery, and the addition of CMC and GMP capabilities gives us the ability to fully integrate lead therapeutic selection, moving key choices earlier, and aligning teams to make a seamless arc of drug development for our partners," said Bo Barnhart, Ph.D., Scientific Director at AbCellera. "We are building a unique team that includes innovative CMC Development leaders, deeply integrated with Discovery and Translational Research, all focused on selecting and developing better therapeutics to go from antibody discovery to fill-finish in a year."

    The facility is scheduled to be ready for GMP manufacturing in early 2024, and at full capacity will employ hundreds of highly skilled scientific personnel. AbCellera anticipates adding hundreds of employees to its current workforce of nearly 300 people over the next few years. The development of the new GMP manufacturing facility is funded in part by a US$125.6-million grant from the Canadian government's Strategic Innovation Fund (SIF) to support AbCellera's work and Canada's ability to respond quickly to future pandemics.

    "I am pleased to see AbCellera participating in our government's effort to reverse a four-decade decline in Canada's domestic capacity," said the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry. "This is an important step toward improving Canada's pandemic preparedness, and a driver for our economic recovery."

    AbCellera is at the forefront of the global COVID-19 response, with its discovery of bamlanivimab, the world's first monoclonal antibody therapy for COVID-19 to be authorized for emergency use by both the U.S. FDA and Health Canada. More than 400,000 doses of bamlanivimab have been administered worldwide, keeping more than 22,000 patients out of hospital, and saving at least 11,000 lives. AbCellera has also discovered a second antibody, LY-CoV1404, that is being advanced by Eli Lilly & Company to address emerging and future variants. This antibody has been shown to be effective against all currently circulating variants of concern and entered clinical trials in May.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. To learn more, please visit us at www.abcellera.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  4. AbCellera (NASDAQ:ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera, and other senior leaders (collectively, the "Selling Shareholders"), have entered into separate share purchase agreements with experienced institutional investors (the "Buyers"), pursuant to which the Buyers purchased an aggregate 11,900,000 common shares ("Shares"). Proceeds from the sale were paid to the Selling Shareholders, and AbCellera did not receive any proceeds.

    Dr. Hansen's sale was in connection with estate planning, technology investing, and charitable giving. Following the sale and the allocation of shares for future charitable donations…

    AbCellera (NASDAQ:ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera, and other senior leaders (collectively, the "Selling Shareholders"), have entered into separate share purchase agreements with experienced institutional investors (the "Buyers"), pursuant to which the Buyers purchased an aggregate 11,900,000 common shares ("Shares"). Proceeds from the sale were paid to the Selling Shareholders, and AbCellera did not receive any proceeds.

    Dr. Hansen's sale was in connection with estate planning, technology investing, and charitable giving. Following the sale and the allocation of shares for future charitable donations, Dr. Hansen remains AbCellera's largest shareholder with 54,354,330 common shares, representing approximately a 20% equity interest on an undiluted basis. Dr. Hansen and other senior executives have not entered into 10b5-1 plans for any future sales of shares.

    The Shares were sold by way of a private sale between individual Selling Shareholders and Buyers, who were already investors in AbCellera. The Selling Shareholders coordinated the private sale in response to inbound inquiries from the Buyers. Following the sale, the Selling Shareholders retain approximately 89% of their total equity holdings, which represent approximately 30% of AbCellera's fully diluted shares. AbCellera filed a Registration Statement on Form S-1 on June 10, 2021 to register the Shares.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. AbCellera conducted its initial public offering in the United States and not in any Canadian jurisdiction.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
    • Total revenue of $203 million, up from $5 million in Q1 2020
    • Total programs under contract of 119, up 63% year-over-year
    • EPS of $0.43 (basic) and $0.37 (diluted) compared to $0.01 loss per share in Q1 2020

    AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2021.

    "Our partnership business continued to thrive in the first quarter of 2021, expanding our diversified program portfolio through collaborations with both new and existing partners," said Carl Hansen, Ph.D., President and CEO of AbCellera. "Royalty revenue from our COVID-19 program continues to provide us with non-dilutive funding, bolstering our strong…

    • Total revenue of $203 million, up from $5 million in Q1 2020
    • Total programs under contract of 119, up 63% year-over-year
    • EPS of $0.43 (basic) and $0.37 (diluted) compared to $0.01 loss per share in Q1 2020

    AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2021.

    "Our partnership business continued to thrive in the first quarter of 2021, expanding our diversified program portfolio through collaborations with both new and existing partners," said Carl Hansen, Ph.D., President and CEO of AbCellera. "Royalty revenue from our COVID-19 program continues to provide us with non-dilutive funding, bolstering our strong cash position as we execute on our long-term growth strategies."

    Q1 2021 Business Highlights

    • Earned $203 million in total revenue, including $178 million in milestones and royalties.
    • Generated $117 million in net earnings, up from a $2 million loss in Q1 2020.
    • Expanded partnership business by 16 programs within the quarter, a 23% increase in the rate of growth from 13 new programs added in the same period in 2020.
    • Achieved cumulative total of 119 programs under contract with 29 partners.
    • Bamlanivimab alone and bamlanivimab together with etesevimab have been authorized under emergency/special use pathways by more than 15 countries worldwide. In the US, bamlanivimab alone is no longer authorized for emergency use, and Lilly has transitioned to exclusively supplying bamlanivimab together with etesevimab to treat COVID-19 in high-risk patients.
    • Identified a second therapeutic antibody for COVID-19, LY-CoV1404, which advanced into clinical trials in April 2021.
    • Appointed Ester Falconer, Ph.D., to Chief Technology Officer.

    Key Business Metrics

    Metric

    March 31,

    2020

    March 31,

    2021

    Change %

    Number of discovery partners

    24

    29

    21%

    Programs under contract, cumulative

    73

    119

    63%

    Program starts, cumulative

    47

    52

    11%

    Programs in the clinic

    -

    1

    N/M

    As of March 31, 2021, the Company had 119 discovery programs (up 63% from 73 on March 31, 2020) that are either completed, in progress, or under contract with 29 partners (up from 24 on March 31, 2020). The Company has started discovery on a cumulative total of 52 of these programs (up from 47 on March 31, 2020).

    Discussion of Q1 2021 Financial Results

     

    Three months ended March 31,

    Change

     

    2020

    2021

    Amount

    %

     

    (in thousands, except percentages)

     

    Revenue

     

     

     

     

     

     

     

     

     

    Research fees

    $

    4,657

    $

    3,986

    $

    (671

    )

    -14

    %

    Licensing revenue

     

    -

     

    20,259

     

    20,259

     

    N/A

     

    Milestone payments

     

    -

     

    7,000

     

    7,000

     

    N/A

     

    Royalty revenue

     

    -

     

    171,496

     

    171,496

     

    N/A

     

    Total revenue

    $

    4,657

    $

    202,741

    $

    198,084

     

    4253

    %

    • Revenue – Total revenue was $202.7 million, up from $4.7 million in Q1 2020. Sales of bamlanivimab generated earned royalties of $171.5 million and $7.0 million for first sales in Europe. Licensing revenue of $20.3 million is a new line on the income statement and originated from the recently acquired Trianni humanized rodent platform. The partnership business produced research fees of $4.0 million, $0.7 million less than in Q1 2020.
    • Royalty Fees – Royalty fees to the National Institutes of Health on bamlanivimab were $20.0 million.
    • Research & Development (R&D) Expenses – R&D expenses were $12.4 million, compared to $4.1 million in Q1 2020, reflecting continuing strong investments in the capacity and capabilities of AbCellera's discovery and development platform.
    • Sales & Marketing (S&M) Expenses – S&M expenses were $2.6 million, compared to $0.4 million in Q1 2020.
    • General & Administrative (G&A) Expenses – G&A expenses were $6.4 million, compared to $1.7 million in 2020, with the increase driven by investments to support the growth of the company and operations as a listed company.
    • Net Earnings – Net earnings were $117.2 million, or $0.43 per share and $0.37 per share on a basic and diluted basis, respectively, compared to a net loss of $2.1 million, or $0.01 per share on both a basic and diluted basis in Q1 2020.
    • Liquidity – $686 million of cash and cash equivalents and $193 million in accrued accounts receivable.

    Conference Call and Webcast

    AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Daylight Time (5:00 p.m. Eastern Daylight Time).

    The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera's Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. To learn more, please visit us at www.abcellera.com.

    Definition of Key Business Metrics

    We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops. For example, as our business matures and to the extent programs are discontinued, we anticipate updating these metrics to reflect such changes.

    Number of discovery partners represents the unique number of partners with whom we have executed partnership contracts. We view this metric as an indication of the competitiveness of our technology stack and our current level of market penetration. The metric also relates to our opportunities to secure programs under contract.

    Programs under contract represent the number of antibody development programs that are under contract for delivery of discovery research activities. A program under contract is counted when a contract is executed with a partner under which we commit to discover antibodies against one selected target. A target is any relevant antigen for which a partner seeks our support in developing binding antibodies. We view this metric as an indication of commercial success and technological competitiveness. It further relates to revenue from technology access fees. The cumulative number of programs under contract with downstream participation is related to our ability to generate future revenue from milestone payments and royalties.

    Program starts represent the number of unique programs under contract for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of our operational capacity to execute on programs under contract. It is also an indication of the selection and initiation of discovery projects by our partners and the resulting near-term potential to earn research fees. Cumulatively, program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties in the mid- to long-term.

    Programs in the clinic represent the count of unique programs for which an Investigational New Drug, or IND, New Animal Drug or Pre-Market Approval, or PMA, application, or equivalents under other regulatory regimes, has been filed based on an antibody that was discovered by us. Where the date of such application is not known to us, the date of the first public announcement of clinical trials will be used instead for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    AbCellera Biologics Inc.

    Condensed Consolidated Statement of Operations

    (Unaudited)

    (Expressed in thousands of U.S. dollars except share and per share data)

     

     

     

    Three months ended March 31,

     

     

    2020

     

    2021

    Revenue:

     

     

     

     

     

     

     

    Research fees

     

    $

    4,657

     

     

    $

    3,986

    Licensing revenue

     

     

    -

     

     

     

    20,259

    Milestone payments

     

     

    -

     

     

     

    7,000

    Royalty revenue

     

     

    -

     

     

     

    171,496

    Total revenue

     

     

    4,657

     

     

     

    202,741

    Operating expenses:

     

     

     

     

     

     

     

    Royalty fees

     

     

    -

     

     

     

    20,010

    Research and development(1)

     

     

    4,118

     

     

     

    12,352

    Sales and marketing(1)

     

     

    437

     

     

     

    2,578

    General and administrative(1)

     

     

    1,650

     

     

     

    6,422

    Depreciation and amortization

     

     

    574

     

     

     

    3,305

    Total operating expenses

     

     

    6,779

     

     

     

    44,667

    Income (loss) from operations

     

     

    (2,122

    )

     

     

    158,074

    Other (income) expense

     

     

     

     

     

     

     

    Other (income) expense

     

     

    1,001

     

     

     

    (265

    )

    Grants and incentives

     

     

    (1,030

    )

     

     

    (3,148

    )

    Total other income

     

     

    (29

    )

     

     

    (3,413

    )

    Net earnings (loss) before income tax

     

     

    (2,093

    )

     

     

    161,487

    Provision for income tax

     

     

    -

     

     

     

    44,266

    Net earnings (loss) and comprehensive income (loss) for the period

     

    $

    (2,093

    )

     

    $

    117,221

    Net earnings (loss) per share attributable to common shareholders

     

     

     

     

     

     

     

    Basic

     

    $

    (0.01

    )

     

    $

    0.43

    Diluted

     

    $

    (0.01

    )

     

    $

    0.37

    Weighted-average common shares outstanding

     

     

     

     

     

     

     

    Basic

     

     

    151,859,924

     

     

     

    269,697,212

    Diluted

     

     

    151,859,924

     

     

     

    320,282,747

     

    (1) Exclusive of depreciation and amortization

     

    AbCellera Biologics Inc.

    Condensed Consolidated Balance Sheet

    (Unaudited)

    (Expressed in thousands of U.S. dollars except share data)

     

     

     

    December 31, 2020

     

     

    March 31, 2021

    Assets

     

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    594,116

     

     

    $

    685,795

    Accounts receivable

     

     

    903

     

     

     

    23,371

    Accrued accounts receivable

     

     

    212,336

     

     

     

    193,071

    Other current assets

     

     

    5,970

     

     

     

    5,745

    Total current assets

     

     

    813,325

     

     

     

    907,982

    Long term assets:

     

     

     

     

     

     

     

    Property and equipment, net

     

     

    17,923

     

     

     

    34,618

    Intangible assets

     

     

    115,153

     

     

     

    112,688

    Goodwill

     

     

    31,500

     

     

     

    31,500

    Investments in and loans to equity accounted investees

     

     

    19,247

     

     

     

    32,187

    Other long-term assets

     

     

    8,388

     

     

     

    9,548

    Total long-term assets

     

     

    192,211

     

     

     

    220,541

    Total assets

     

    $

    1,005,536

     

     

    $

    1,128,523

    Liabilities and shareholders' equity

     

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

     

    Accounts payable and other liabilities

     

    $

    20,195

     

     

    $

    13,287

    Current portion of contingent consideration payable

     

     

    13,411

     

     

     

    13,762

    Income taxes payable

     

     

    36,152

     

     

     

    30,030

    Accrued royalties payable

     

     

    27,143

     

     

     

    20,010

    Deferred revenue

     

     

    6,589

     

     

     

    11,306

    Total current liabilities

     

     

    103,490

     

     

     

    88,395

    Long-term liabilities:

     

     

     

     

     

     

     

    Operating lease liability

     

     

    3,715

     

     

     

    16,973

    Deferred revenue and grant funding

     

     

    25,894

     

     

     

    28,730

    Contingent consideration payable

     

     

    9,148

     

     

     

    9,378

    Deferred tax liability

     

     

    26,161

     

     

     

    26,992

    Other long-term liabilities

     

     

    6,620

     

     

     

    931

    Total long-term liabilities

     

     

    71,538

     

     

     

    83,004

    Total liabilities

     

     

    175,028

     

     

     

    171,399

    Commitments and contingencies

     

     

     

     

     

     

     

    Shareholders' equity:

     

     

     

     

     

     

     

    Common shares: no par value, unlimited authorized shares at December 31, 2020 and March 31, 2021: 269,497,768 and 270,925,930 shares issued and outstanding at December 31, 2020 and March 31, 2021 respectively

     

     

    710,387

     

     

     

    711,139

    Additional paid-in capital

     

     

    5,919

     

     

     

    14,562

    Accumulated earnings

     

     

    114,202

     

     

     

    231,423

    Total shareholders' equity

     

     

    830,508

     

     

     

    957,124

    Total liabilities and shareholders' equity

     

    $

    1,005,536

     

     

    $

    1,128,523

    AbCellera Biologics Inc.

    Condensed Consolidated Statement of Cash Flows

    (Unaudited)

    (Expressed in thousands of U.S. dollars)

     

     

     

    Three months ended March 31,

     

     

    2020

     

    2021

    Cash flows from operating activities:

     

     

     

     

     

     

     

     

    Net income (loss)

     

    $

    (2,093

    )

     

    $

    117,221

     

    Cash flows from operating activities:

     

     

     

     

     

     

     

     

    Depreciation of property and equipment

     

     

    415

     

     

     

    840

     

    Amortization of intangible assets

     

     

    158

     

     

     

    2,465

     

    Amortization of operating lease right-of-use-assets

     

     

    73

     

     

     

    661

     

    Stock-based compensation

     

     

    1,237

     

     

     

    5,427

     

    Deferred tax expense

     

     

    -

     

     

     

    623

     

    Other

     

     

    (28

    )

     

     

    (191

    )

    Changes in operating assets and liabilities:

     

     

     

     

     

     

     

     

    Accounts and accrued research fees receivable

     

     

    (26,611

    )

     

     

    (30,073

    )

    Accrued royalties receivable

     

     

    -

     

     

     

    26,861

     

    Income taxes payable

     

     

    -

     

     

     

    (6,123

    )

    Accounts payable and accrued liabilities

     

     

    (156

    )

     

     

    (5,194

    )

    Deferred revenue

     

     

    27,676

     

     

     

    6,086

     

    Accrued royalties payable

     

     

    -

     

     

     

    (7,134

    )

    Other assets and liabilities

     

     

    (1,435

    )

     

     

    (1,924

    )

    Net cash (used in) provided by operating activities

     

     

    (764

    )

     

     

    109,545

     

    Cash flows from investing activities:

     

     

     

     

     

     

     

     

    Purchases of property and equipment

     

     

    (583

    )

     

     

    (3,644

    )

    Purchase of intangible assets

     

     

    (5,000

    )

     

     

    -

     

    Investment in equity investees

     

     

    -

     

     

     

    (12,195

    )

    Net cash used in investing activities

     

     

    (5,583

    )

     

     

    (15,839

    )

    Cash flows from financing activities:

     

     

     

     

     

     

     

     

    Repayment of long-term debt

     

     

    (2,033

    )

     

     

    (1,716

    )

    Proceeds from long-term debt

     

     

    16,171

     

     

     

    -

     

    Payment of deferred financing fees

     

     

    (799

    )

     

     

    -

     

    Short-term borrowings

     

     

    (387

    )

     

     

    -

     

    Issuance of common shares pursuant to exercise of stock options

     

     

    124

     

     

     

    173

     

    Proceeds from issuance of preferred shares - series A2 financing

     

     

    74,662

     

     

     

    -

     

    Net cash provided by (used in) financing activities

     

     

    87,738

     

     

     

    (1,543

    )

    Effect of exchange rate changes on cash and cash equivalents

     

     

     

     

     

     

    (484

    )

    Increase in cash and cash equivalents

     

     

    81,391

     

     

     

    91,679

     

    Cash and cash equivalents, beginning of period

     

     

    7,553

     

     

     

    594,116

     

    Cash and cash equivalents, end of period

     

    $

    88,944

     

     

    $

    685,795

     

    Supplemental disclosure of non-cash investing and financing activities

     

     

     

     

     

     

     

     

    Property plant and equipment in accounts payable

     

     

    95

     

     

     

    423

     

    Right-of-use assets obtained in exchange for operating lease obligation

     

    741

     

     

     

    14,188

    Purchase of intangible assets in exchange for in-licensing agreement payable

     

     

    9,060

     

     

     

    -

     

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  5. AbCellera (NASDAQ:ABCL) today announced that executives from the Company will present virtually at the Berenberg Conference USA 2021 on Tuesday, May 18, 2021 at 11:00 a.m. Pacific Time.

    A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move…

    AbCellera (NASDAQ:ABCL) today announced that executives from the Company will present virtually at the Berenberg Conference USA 2021 on Tuesday, May 18, 2021 at 11:00 a.m. Pacific Time.

    A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. To learn more, please visit us at www.abcellera.com.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  6. Three-target, multi-year collaboration includes the development of bispecific antibodies to treat sight-threatening complication of type 1 and 2 diabetes

    AbCellera (NASDAQ:ABCL) and Angios GmbH (Angios) announced today that they have entered into a multi-year, multi-target collaboration to facilitate the discovery of monoclonal and bispecific antibodies for vascular diseases of the eye. AbCellera will use its full stack, AI-powered antibody discovery platform to generate panels of antibodies for up to three Angios-selected targets to address diabetic retinopathy.

    "Through this collaboration, Angios can focus on advancing their unique scientific insights for treating blindness in diabetes, rather than on establishing and scaling internal antibody…

    Three-target, multi-year collaboration includes the development of bispecific antibodies to treat sight-threatening complication of type 1 and 2 diabetes

    AbCellera (NASDAQ:ABCL) and Angios GmbH (Angios) announced today that they have entered into a multi-year, multi-target collaboration to facilitate the discovery of monoclonal and bispecific antibodies for vascular diseases of the eye. AbCellera will use its full stack, AI-powered antibody discovery platform to generate panels of antibodies for up to three Angios-selected targets to address diabetic retinopathy.

    "Through this collaboration, Angios can focus on advancing their unique scientific insights for treating blindness in diabetes, rather than on establishing and scaling internal antibody discovery capabilities," said Carl Hansen, Ph.D., CEO and President of AbCellera. "We are excited to work closely with Angios to start their programs without delay, including identifying bispecific antibodies against diabetic retinopathy, and moving them forward at maximum speed."

    Diabetic retinopathy, which is a complication of type 1 and 2 diabetes, is caused by chronic hyperglycemia and is the leading cause of preventable visual impairment and blindness in working-age adults. Patients with diabetes who have an increased risk of developing retinopathy include those with comorbid hypertension and dyslipidemia.1,2

    "As a young biotech, we have to use our resources efficiently to maximize the development of novel therapeutics for growing numbers of patients affected by this life-altering disease," said Gregor Wick, Ph.D., CEO of Angios. "Our partnership with AbCellera will greatly improve our ability to realize our ambitious goals to accelerate therapeutic development so patients can get meaningful new therapies as soon as possible."

    "There are 400 million patients with diabetes, and the numbers are rapidly growing," said Josef Penninger, Ph.D., Chairman of Angios. "Changes in blood vessels are the major cause for diabetic symptoms such as kidney failure, heart attacks, non-healing wounds, and also blindness. There is an enormous unmet medical need to develop novel therapies for these patients."

    Under the terms of the agreement, Angios will have the rights to develop and commercialize therapeutic products resulting from the collaboration. AbCellera will receive equity and research fees and is eligible for milestone payments and royalties based on the development and commercialization of antibodies generated by AbCellera under this collaboration.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

    About Angios

    Angios GmbH (Angios) is a biotechnology company specializing in developing therapeutics for vascular diseases with a vision of improving standard of care for diabetic retinopathy. Founded in 2021 and based in Innsbruck, Austria, Angios strives to develop new treatments for challenging vascular diseases by pursuing pre-identified targets for diabetic retinopathy and by leveraging the vascular organoid model developed in the laboratories of our founders.

    For more information, visit www.angios-bio.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    1 Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-136. doi:10.1016/S0140-6736(09)62124-3

    2 Ghamdi AHA. Clinical Predictors of Diabetic Retinopathy Progression; A Systematic Review. Curr Diabetes Rev. 2020;16(3):242-247. doi:10.2174/1573399815666190215120435

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  7. -        New preclinical data show that LY-CoV1404 binds and neutralizes all currently known circulating SARS-CoV-2 variants of concern

    -        LY-CoV1404 binds to a rarely mutated region of the SARS-CoV-2 spike protein, suggesting effectiveness against emerging variants

    -        LY-CoV1404 neutralizes authentic SARS-CoV-2 with high potency in vitro

    -        LY-CoV1404 enters clinical trials as part of Lilly's BLAZE-4 study in patients with mild-to-moderate COVID-19 illness

    AbCellera (NASDAQ:ABCL) today announced that a second antibody from its collaboration with Eli Lilly and Company (Lilly), LY-CoV1404, has entered clinical trials in patients with mild-to-moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trials to evaluate…

    -        New preclinical data show that LY-CoV1404 binds and neutralizes all currently known circulating SARS-CoV-2 variants of concern

    -        LY-CoV1404 binds to a rarely mutated region of the SARS-CoV-2 spike protein, suggesting effectiveness against emerging variants

    -        LY-CoV1404 neutralizes authentic SARS-CoV-2 with high potency in vitro

    -        LY-CoV1404 enters clinical trials as part of Lilly's BLAZE-4 study in patients with mild-to-moderate COVID-19 illness

    AbCellera (NASDAQ:ABCL) today announced that a second antibody from its collaboration with Eli Lilly and Company (Lilly), LY-CoV1404, has entered clinical trials in patients with mild-to-moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trials to evaluate LY-CoV1404 alone and together with other monoclonal antibodies.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504005494/en/

    Top: Side view of a model of LY-COV1404 Fabs (target-binding fragments of the antibody, green) bound to SARS-CoV-2 spike protein (grey) mapped with key mutations from all six variants of concern (red). Bottom: Top views of a model of LY-CoV1404 Fabs (target-binding fragments of the antibody, green) bound to SARS-CoV-2 spike protein (grey) mapped with key mutations of each variant of concern (red). (Photo: AbCellera)

    Top: Side view of a model of LY-COV1404 Fabs (target-binding fragments of the antibody, green) bound to SARS-CoV-2 spike protein (grey) mapped with key mutations from all six variants of concern (red). Bottom: Top views of a model of LY-CoV1404 Fabs (target-binding fragments of the antibody, green) bound to SARS-CoV-2 spike protein (grey) mapped with key mutations of each variant of concern (red). (Photo: AbCellera)

    In support of this clinical study, AbCellera released preclinical data showing LY-CoV1404 binds to a rarely mutated region of the SARS-CoV-2 spike protein and neutralizes all currently known variants of concern, including those first identified in the UK (B.1.1.7), South Africa (B.1.351), Brazil (P.1), California (B.1.426 and B.1.429), and New York (B.1.526). LY-CoV1404 is highly potent, which could have implications for reducing the amount of antibody necessary for clinical dosing, and potentially enabling a subcutaneous route of administration for either treatment or prophylaxis of COVID-19.

    "When we first mobilized against COVID-19 in March of last year, we made a decision to develop a single antibody, emphasizing speed and scalability so that we could help as many patients as possible, as quickly as possible. That antibody, bamlanivimab (LY-CoV555), was the first to receive FDA Emergency Use Authorization and has treated more patients than any other neutralizing antibody – preventing more than 22,000 hospitalizations and 11,000 deaths in the U.S. alone," said Carl Hansen, Ph.D., CEO of AbCellera. "Knowing that additional neutralizing antibodies would be needed to combat emerging variants, we continued to screen patient samples, and identified LY-CoV1404. Our analysis of LY-CoV1404 shows that it is exceptionally potent and neutralizes currently known variants of concern. We are encouraged by the potential of LY-CoV1404 to provide a long-term complement to vaccines in the likely event that COVID-19 becomes endemic. Our partner Lilly, who has been a leader in rapidly developing, testing, and globally supplying COVID-19 antibody treatments, has advanced LY-CoV1404 into the clinic as part of its ongoing BLAZE-4 trial."

    LY-CoV1404 is developed from a fully human monoclonal antibody identified from a blood sample obtained approximately 60 days after symptom onset from a convalescent COVID-19 patient. Preclinical data show LY-CoV1404 potently neutralizes SARS-CoV-2 and all current variants identified and reported to be of concern in this pandemic. LY-CoV1404 blocks viral binding to ACE2 by targeting a highly conserved epitope on the SARS-CoV-2 spike glycoprotein receptor binding domain (RBD), providing a strong, well-documented mechanism for the potent neutralizing activity. Furthermore, LY-CoV1404 is substantially more potent in viral neutralization assays compared to other broadly neutralizing antibodies.

    "The ability of SARS-CoV-2 variants to negatively alter the trajectory of the pandemic emphasizes the essential need for antibody therapies that can be developed in real time to combat the virus as it evolves," said Bo Barnhart, Ph.D., Scientific Director at AbCellera. "LY-CoV1404's powerful neutralization of SARS-CoV-2 allows for exploration of lower clinical doses, which may support subcutaneous administration and availability of more doses to treat patients around the world."

    LY-CoV1404 uniquely binds a conserved region of the SARS-CoV-2 RBD that is distinct from other neutralizing antibodies. While the LY-CoV1404 binding epitope includes amino acid residues N501 and N439, LY-CoV1404 neutralizes B.1.1.7 and B.1.351, which both carry the N501Y mutation, as potently as wild type virus in pseudovirus assays and retains full functional neutralization against pseudovirus with the N439K mutant. An in-depth assessment of mutations that could inhibit neutralization of LY-CoV1404 identified two specific amino acid positions that are very rarely mutated in the general population (0.027%), as reported in the GISAID database as of April 2021. The potent activity of LY-CoV1404 against the currently known variants of concern and against pseudoviruses carrying various single amino acid mutations suggests that LY-CoV1404 binds to an epitope that is highly conserved across all SARS-CoV-2 isolates that have been collected worldwide.

    "Since the identification of bamlanivimab in our first response, we have continued our efforts to build a panel of well-characterized antibodies that have the potential to be deployed rapidly to address emerging variants," said Ester Falconer, Ph.D., Chief Technology Officer at AbCellera. "This strategy and the ability of our tech stack to deeply search and efficiently analyze human immune responses to COVID-19 enabled the discovery of LY-CoV1404. The high neutralization potency of LY-CoV1404 to known SARS-CoV-2 variants and a variety of single amino acid mutations that have been shown to diminish the activity of several other neutralizing antibodies, supports the therapeutic potential of LY-CoV1404 to address current and emerging variants and reduce COVID-19-related illness and death."

    The preclinical data for LY-CoV1404 can be found at https://doi.org/10.1101/2021.04.30.442182.

    About AbCellera's Response to COVID-19

    AbCellera initially mobilized its pandemic response platform against COVID-19 in March of 2020, resulting in the discovery of bamlanivimab, the first monoclonal antibody therapy for COVID-19 to reach human testing and to be authorized for emergency use by the U.S. FDA. Bamlanivimab alone and together with other antibodies has treated hundreds of thousands of patients, preventing COVID-19-related hospitalizations and death.  Bamlanivimab alone and together with other antibodies has been authorized under emergency/special use pathways by more than 15 countries worldwide. In the U.S., bamlanivimab is currently only authorized for emergency use with etesevimab.

    AbCellera's ongoing efforts to respond to the COVID-19 pandemic have identified thousands of unique anti-SARS-CoV-2 human antibodies. These include bamlanivimab, LY-CoV1404, and other antibodies that are in various stages of testing by AbCellera and its partners.

    AbCellera's pandemic response capabilities were developed over the past three years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  8. 380,000 square feet of facilities envisioned as creative tech hub where leading software, engineering, and bioscience talent can solve key problems to accelerate the discovery of new antibody treatments

    AbCellera (NASDAQ:ABCL), a technology company that has developed a centralized operating system for next-generation antibody discovery and development, today announced it has broken ground on an expanded global headquarters in its home city of Vancouver in anticipation of adding hundreds of employees to its current 250-person workforce over the next few years.

    "We're building state-of-the-art facilities in Vancouver to accelerate the development of new antibody therapies with biotech and pharma partners from around the world," said Carl Hansen…

    380,000 square feet of facilities envisioned as creative tech hub where leading software, engineering, and bioscience talent can solve key problems to accelerate the discovery of new antibody treatments

    AbCellera (NASDAQ:ABCL), a technology company that has developed a centralized operating system for next-generation antibody discovery and development, today announced it has broken ground on an expanded global headquarters in its home city of Vancouver in anticipation of adding hundreds of employees to its current 250-person workforce over the next few years.

    "We're building state-of-the-art facilities in Vancouver to accelerate the development of new antibody therapies with biotech and pharma partners from around the world," said Carl Hansen, Ph.D., CEO and President of AbCellera. "We intend for this technology campus to serve as a place where talented people can contribute to dramatically improving and accelerating antibody discovery for the benefit of patients everywhere."

    Located on 4th Avenue between Columbia and Manitoba Streets in Mount Pleasant, the company's planned tech campus includes two facilities totaling 380,000 square feet that will be developed in partnership with the Dayhu Group and Beedie. The facilities are expected to be completed in 2023 and 2024.

    "As a Vancouver-based company, AbCellera's success in leading the fight against COVID-19 underscores how our city has emerged as an innovation hub where tech companies can grow and thrive," said Vancouver Mayor Kennedy Stewart. "The tech sector is a key economic driver for our city, and this announcement ensures that one of our most successful anchor companies will play a pivotal role in creating new jobs, diversifying our economy, and commercializing made-in-BC innovations – all while protecting us from current and emerging health challenges."

    AbCellera's antibody drug discovery platform uses microfluidics, machine learning, computation, custom robotics, and automation to search and analyze natural immune systems at record speed and depth. Hansen noted that the complexity of the technology stack, along with the fact that it is being used in entirely new ways to search, decode, and analyze antibodies, requires a uniquely skilled workforce.

    "Vancouver is home to a wealth of talent and a network of world-leading tech companies and startups," said Véronique Lecault, Ph.D., AbCellera's Chief Operating Officer. "We see this new site as a creative hub for engineers, software developers, data scientists, biologists and bioinformaticians to collaborate, innovate, and push the frontiers of technology. Our company puts significant value on ambitious, adventurous thinkers who are energized by solving hard, important problems in entirely new ways."

    AbCellera's long-term vision in Vancouver includes building Canada's first clinical-grade Good Manufacturing Practice (GMP) antibody manufacturing facility, which will provide technology and infrastructure to help Canada respond to future pandemics.

    Vancouver is a fast-growing technology center in North America, attracting startups with a business environment friendly to young companies, and luring top talent with a sophisticated urban lifestyle, extraordinary outdoor amenities, and stunning natural landscapes.

    About Dayhu Group of Companies

    Dayhu Group of Companies is a leading real estate investment, development, and property management company with over four million square feet of industrial, commercial and retail properties across Western Canada. Founded in 1956, Dayhu is a Vancouver-based, family-managed and owned business. For more information, please visit https://dayhu.com/.

    About Beedie

    Founded in 1954, Beedie is Western Canada's largest private industrial developer and property manager, having completed more than 30 million square feet of new development, with an ever-expanding portfolio of over 11 million square feet. With over six decades of building for good, Beedie is also one of the Lower Mainland's most reputable residential developers having completed several significant, large-scale master-planned communities and mixed-use projects. For more information, please visit https://www.beedie.ca/.

    About AbCellera Biologics

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  9. AbCellera (NASDAQ:ABCL) will announce its first-quarter 2021 financial results on Thursday, May 13, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

    A live webcast will be available on AbCellera's Investor Relations website at: https://investors.abcellera.com/. Replay of the webcast will be available through the same link following the conference call.

    About AbCellera

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move…

    AbCellera (NASDAQ:ABCL) will announce its first-quarter 2021 financial results on Thursday, May 13, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

    A live webcast will be available on AbCellera's Investor Relations website at: https://investors.abcellera.com/. Replay of the webcast will be available through the same link following the conference call.

    About AbCellera

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. To learn more, please visit www.abcellera.com.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  10. AbCellera (NASDAQ:ABCL) and Empirico Inc. ("Empirico") announced today that they have entered into a strategic multi-target discovery collaboration. Through each company's proprietary technologies, the multi-target collaboration leverages hyper-scale datasets, machine learning, and advanced computation to both identify high-value, genetically-validated drug targets and discover novel therapeutic antibodies. Empirico will use its Precision Insights Platform, a human genetics-focused discovery platform, to select up to five therapeutic targets. AbCellera will use its AI-powered antibody discovery technology to search and analyze natural immune responses to identify antibodies with the desired therapeutic properties against the selected targets…

    AbCellera (NASDAQ:ABCL) and Empirico Inc. ("Empirico") announced today that they have entered into a strategic multi-target discovery collaboration. Through each company's proprietary technologies, the multi-target collaboration leverages hyper-scale datasets, machine learning, and advanced computation to both identify high-value, genetically-validated drug targets and discover novel therapeutic antibodies. Empirico will use its Precision Insights Platform, a human genetics-focused discovery platform, to select up to five therapeutic targets. AbCellera will use its AI-powered antibody discovery technology to search and analyze natural immune responses to identify antibodies with the desired therapeutic properties against the selected targets.

    Under the terms of the agreement, Empirico will have the rights to develop and commercialize novel antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products from Empirico.

    "One of the biggest challenges in drug development is the lack of translation between preclinical models and human disease. Empirico's platform seeks to overcome this hurdle by uncovering causal relationships between human genetic variation and clinical outcomes to discover and validate targets," said Carl Hansen, Ph.D., CEO and President of AbCellera. "We are excited to partner with Empirico and serve as its operating system for developing new antibody-based therapies against genetically-validated targets."

    "Using our Precision Insights Platform, Empirico has discovered multiple genetically-validated targets for diseases with unmet medical need, several of which are amenable to modulation with therapeutic antibodies," said Omri Gottesman, M.D., CEO and President of Empirico. "For these and future programs, our partnership with AbCellera empowers and enables us to rapidly translate therapeutic insights from human genetics into potential new medicines for patients in need."

    About Empirico Inc.

    Empirico is a next-generation therapeutics company founded on utilizing human genetics, data science and programmable biology to power novel target discovery and development. Empirico's Precision Insights Platform, a proprietary human genetics-focused discovery platform, leverages a world-leading dataset, hyperscale infrastructure and algorithmic approaches that encode and enhance human intuition to identify and prioritize therapeutic targets. All potential therapeutic targets are subjected to rigorous in vitro and in vivo experimental validation to elucidate the mechanism by which genetic variation impacts disease risk and provide insights about which therapeutic modality could be ‘programmed' to mimic or interfere with that mechanism. Empirico is advancing multiple preclinical programs across a broad range of indications and therapeutic modalities, both independently and in collaboration with industry partners. Empirico is headquartered in San Diego, Calif. with laboratories in Madison, Wis. To learn more about Empirico, visit www.empiricotx.com.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. www.abcellera.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  11. AbCellera (NASDAQ:ABCL) today announced that executives from the Company will present at the following virtual investor conferences:

    • BMO Biopharma Spotlight Series: Technology-Enabled Drug Discovery Panel on Friday, April 16, 2021 at 7:00 a.m. Pacific Time
    • 2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20 at 10:30 a.m. Pacific Time

    Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website. A replay of each webcast will be available through the same links following the presentation.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners…

    AbCellera (NASDAQ:ABCL) today announced that executives from the Company will present at the following virtual investor conferences:

    • BMO Biopharma Spotlight Series: Technology-Enabled Drug Discovery Panel on Friday, April 16, 2021 at 7:00 a.m. Pacific Time
    • 2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20 at 10:30 a.m. Pacific Time

    Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website. A replay of each webcast will be available through the same links following the presentation.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. To learn more, please visit us at www.abcellera.com.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  12. - Bamlanivimab (LY-CoV555) has greater affinity and potency relative to other RBD-binding and ACE2-blocking antibodies tested in this study

    - Because of its potency, bamlanivimab provides a therapeutic foundation to be administered with another antibody to expand the protection against viral variants

    - Study was the first of its kind to show a neutralizing antibody can decrease SARS-CoV-2 viral shedding and transmission by blocking virus replication in the upper airway

    - Bamlanivimab moved from first screen to clinical testing in 90 days1 and is the world's first monoclonal antibody specifically developed against SARS-CoV-2 to receive FDA Emergency Use Authorization (EUA)2

    - Since EUA, bamlanivimab has been used to treat approximately 400,000

    - Bamlanivimab (LY-CoV555) has greater affinity and potency relative to other RBD-binding and ACE2-blocking antibodies tested in this study

    - Because of its potency, bamlanivimab provides a therapeutic foundation to be administered with another antibody to expand the protection against viral variants

    - Study was the first of its kind to show a neutralizing antibody can decrease SARS-CoV-2 viral shedding and transmission by blocking virus replication in the upper airway

    - Bamlanivimab moved from first screen to clinical testing in 90 days1 and is the world's first monoclonal antibody specifically developed against SARS-CoV-2 to receive FDA Emergency Use Authorization (EUA)2

    - Since EUA, bamlanivimab has been used to treat approximately 400,000 high-risk COVID-19 patients in the U.S. alone and has been authorized in more than 15 countries

    AbCellera (NASDAQ:ABCL) and collaborators today announced the publication of research in Science Translational Medicine characterizing the high potency of bamlanivimab (LY-CoV555) to neutralize SARS-CoV-2 by uniquely binding both the up and down confirmations of the spike receptor-binding domain (RBD) and inhibiting critical interactions with the angiotensin converting enzyme 2 (ACE2) cellular receptor necessary for viral entry. Data generated in a preclinical model showed prophylactic treatment with bamlanivimab resulted in significant decreases in viral load and replication in the upper and lower respiratory tracts after SARS-CoV-2 exposure, indicating the potential of bamlanivimab to reduce viral shedding and transmission. These data, which were generated prior to initiating clinical trials in June 2020 and published today, support the observed substantial clinical efficacy of bamlanivimab in treating and preventing COVID-19.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210405005386/en/

    The unique binding of bamlanivimab to the SARS-CoV-2 spike protein: The spike protein exists as a trimer of three identical monomers on the surface of the SARS-CoV-2 virus. Structural modeling (left panel) of the spike trimer in shades of pink and white is shown with the target-binding fragments (Fabs) of bamlanivimab (in green and yellow) bound to the RBD of the spike protein. This analysis shows three bamlanivimab Fab fragments bound to one spike trimer. One of the spike proteins is in the up position (dark pink) with the other two in the down position (light pink and white). The middle panel shows an isolated view of the spike monomers (dark pink, white and light pink) with the bound bamlanivimab Fab fragments in green and yellow. In the right panel, two spike monomers bound in the up and down positions by the bamlanivimab Fab fragments are overlaid. 3D structural model provided by JS McLellan Group, University of Texas.

    The unique binding of bamlanivimab to the SARS-CoV-2 spike protein: The spike protein exists as a trimer of three identical monomers on the surface of the SARS-CoV-2 virus. Structural modeling (left panel) of the spike trimer in shades of pink and white is shown with the target-binding fragments (Fabs) of bamlanivimab (in green and yellow) bound to the RBD of the spike protein. This analysis shows three bamlanivimab Fab fragments bound to one spike trimer. One of the spike proteins is in the up position (dark pink) with the other two in the down position (light pink and white). The middle panel shows an isolated view of the spike monomers (dark pink, white and light pink) with the bound bamlanivimab Fab fragments in green and yellow. In the right panel, two spike monomers bound in the up and down positions by the bamlanivimab Fab fragments are overlaid. 3D structural model provided by JS McLellan Group, University of Texas.

    Previously Reported Clinical Trial Results

    Bamlanivimab has been evaluated both alone and together with other antibodies in more than 5,000 patients across multiple clinical trials and is currently authorized in more than 15 countries. Bamlanivimab alone versus placebo has been shown to reduce hospitalization by 70% in high-risk patients with early COVID-19 infection3 and reduce the risk of contracting COVID-19 by up to 80% in nursing home residents when used as a prophylactic.4

    Because of its potency, bamlanivimab also provides a therapeutic foundation to be administered with other antibodies to expand the protection against viral variants. The first of these, bamlanivimab together with etesevimab, has been authorized in the U.S. and within the European Union, and Phase 3 data show that this antibody therapy reduces COVID-19-related hospitalizations and death by 87%.5 Most importantly, across all the clinical trials, all COVID-19-related deaths occurred in patients taking the placebo; no deaths occurred in patients who received an antibody therapy, either bamlanivimab alone or together with another antibody.5

    "At the beginning of our pandemic response to COVID-19, we made a decision with our partners and collaborators to develop a single antibody, emphasizing speed and scalability so that we would be able to help as many people as possible," said Carl Hansen, Ph.D., CEO and President of AbCellera. "Over the past four months, bamlanivimab has been used to treat hundreds of thousands of people across the world -- more than any other COVID-19 antibody therapy. We believe this has kept thousands of people out of the hospital, reducing the burden on our healthcare systems, and, most importantly, has saved thousands of lives."

    Discussion of Data Published Today in Science Translational Medicine

    Data from multiple in vitro assays of the 24 lead antibodies identified by AbCellera and collaborators indicated bamlanivimab displayed greater neutralization potency despite similar RBD-binding affinities, suggesting bamlanivimab has a unique binding profile to the SARS-CoV-2 spike protein. Structural analysis using X-ray crystallography and electron microscopy demonstrated that bamlanivimab binds to an area on the spike protein overlapping the ACE2 binding site that is predicted to be fully accessible in both the up and down conformations. The RBD portion of the spike protein is the primary target for virus neutralization as it mediates the conserved mechanism of viral entry to infect cells. The spike exists in an up or down position, with the up position enabling interaction with the ACE2 receptor and the down position potentially contributing to immune system evasion. Regardless of the state of the spike protein, bamlanivimab has high binding potency to the RBD of SARS-CoV-2 spike protein.

    "The unique ability of bamlanivimab to bind the spike protein in both the up and down position could underlie bamlanivimab's greater neutralization potency compared to other antibodies," said Bo Barnhart, Ph.D., Scientific Director at AbCellera. "These preclinical data show that modest doses of bamlanivimab provided protection against SARS-CoV-2 infection, which has since been confirmed in clinical trials to protect residents and staff in long-term care facilities and nursing homes. Neutralizing antibodies, like bamlanivimab, are designed to protect our most vulnerable populations for whom vaccines are less effective. These data with bamlanivimab further confirm that neutralizing antibodies have the potential to reduce SARS-CoV-2 viral transmission and prevent infection and can provide immediate benefit when a life-saving treatment is needed."

    To determine the potential of neutralizing antibodies to prevent SARS-CoV-2 infection, nonhuman primates (NHPs) were prophylactically treated with 1, 2.5, 15, or 50 mg/kg of bamlanivimab 24 hours prior to viral challenge. Critically, viral replication as well as viral load were significantly reduced in the upper respiratory tract on Day 1 at multiple doses. Additionally, viral load and replication were significantly reduced or undetectable in the lower respiratory tract at several doses. At doses of 2.5 mg/kg and higher serum concentrations were associated with maximal protection in this model.

    "The data published today give insights into why bamlanivimab is so potent and further support all of our clinical experience and data showing that bamlanivimab is a safe and effective therapy to treat and prevent COVID-19, when administered early in the course of infection," said Ester Falconer, Ph.D., Chief Technology Officer at AbCellera and senior author of the paper. "Furthermore, bamlanivimab's unique potency allows for lower dosing and enables administration with another antibody to address SARS-CoV-2 variants. Over the past year, we have continued to screen patient samples, identifying thousands of human antibodies and generating massive amounts of information about how the human immune system responds to COVID-19. We have tracked the variants closely and identified a next-generation antibody that is predicted to neutralize all circulating variant strains of concern of SARS-CoV-2. This antibody, currently referred to as 1404, moved into preclinical development and manufacturing in January with our partner, Eli Lilly and Company, and we are continuing to work closely with them and our collaborators for rapid advancement."

    The preclinical data for bamlanivimab was published online today in Science Translational Medicine and can be found at: https://science.sciencemag.org/lookup/doi/10.1126/science.abf1906.

    About AbCellera's Response to COVID-19

    Bamlanivimab was developed from an antibody that was discovered from the blood of a recovered COVID-19 patient using AbCellera's pandemic response platform, in partnership with the Vaccine Research Center (VRC) at National Institute of Allergy and Infectious Diseases (NIAID). Within one week of receiving the sample, AbCellera screened over five million antibody-producing cells to identify and isolate approximately 500 unique antibodies that bind to SARS-CoV-2, the virus that causes COVID-19. The binding antibodies were then tested by AbCellera, the VRC, and Eli Lilly and Company (Lilly) to find those most effective in neutralizing the virus. Bamlanivimab was selected as the lead candidate from this group of antibodies and was the first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials in North America. Bamlanivimab was the first monoclonal antibody to receive EUA from the FDA and is currently being assessed in several clinical trials alone and together with other antibodies.

    AbCellera's pandemic response capabilities were developed over the past three years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen. AbCellera's ongoing efforts to respond to the pandemic have identified more than 2,300 unique anti-SARS-CoV-2 human antibodies from multiple patient samples. These antibodies are in various stages of testing by AbCellera and its partners.

    About Bamlanivimab (LY-CoV555)

    Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at NIAID VRC. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

    Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

    Bamlanivimab alone and together with etesevimab are authorized under special/emergency pathways, in the context of the pandemic, in the U.S. and the European Union. In addition, bamlanivimab alone is authorized for emergency use in Canada, Panama, Kuwait, the UAE, Israel, Rwanda, Morocco and numerous other countries. Through Lilly's work with the Bill & Melinda Gates Foundation, Lilly is providing doses of bamlanivimab free of charge in Rwanda and Morocco.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    __________________________

    1 AbCellera's Rapid Pandemic Response Platform Contributes to the World's First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment. June 1, 2020. https://www.abcellera.com/news/2020-06-01-worlds-first-covid-19-clinical-trial-for-a-potential-monoclonal-antibody-treatment

    2 AbCellera-Discovered Antibody Receives U.S. FDA Emergency Use Authorization as a Monotherapy for the Treatment of COVID-19, November 9, 2020. https://www.abcellera.com/news/2020-11-09-bamlanivimab-us-fda-eua

    3 Interim Data Reported for AbCellera-Discovered COVID-19 Antibody in Phase 2 Clinical Trials

    https://www.abcellera.com/news/2020-09-16-interim-data-phase-2-clinical-trials

    4 AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents, January 21, 2021. https://www.abcellera.com/news/2021-01-21-abcellera-discovered-antibody-prevented-covid-19-in-nursing-homes

    5 AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19, March 10, 2021. https://www.abcellera.com/news/2021-03-10-bamlanivimab-together-with-etesevimab-reduced-hospitalizations-and-prevented-death-in-phase-3-trial-for-early-covid-19

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  13. Expanded collaboration includes an eight-target discovery partnership leveraging AbCellera's entire technology stack, including the Trianni Mouse® and the OrthoMabTM bispecific platforms

    AbCellera (NASDAQ:ABCL) today announced agreements to expand its collaboration with Gilead Sciences, Inc. (Gilead) including a multi-year, multi-target antibody discovery collaboration and access to AbCellera's humanized mouse technology, the Trianni Mouse®. Under the financial terms of the agreements, AbCellera will receive an upfront payment and is eligible for milestone payments and royalties based on the development and commercialization of antibodies generated by AbCellera under this collaboration.

    Building on the successful completion of the first collaboration…

    Expanded collaboration includes an eight-target discovery partnership leveraging AbCellera's entire technology stack, including the Trianni Mouse® and the OrthoMabTM bispecific platforms

    AbCellera (NASDAQ:ABCL) today announced agreements to expand its collaboration with Gilead Sciences, Inc. (Gilead) including a multi-year, multi-target antibody discovery collaboration and access to AbCellera's humanized mouse technology, the Trianni Mouse®. Under the financial terms of the agreements, AbCellera will receive an upfront payment and is eligible for milestone payments and royalties based on the development and commercialization of antibodies generated by AbCellera under this collaboration.

    Building on the successful completion of the first collaboration together, under the new agreement AbCellera will generate panels of antibodies for up to eight new targets, across multiple indications, selected by Gilead. The expanded collaboration will leverage the full breadth of AbCellera's technology stack, including the recently added capabilities for sourcing diverse, fully-humanized antibodies using the Trianni Mouse® platform and combining any two antibodies to create native bispecifics using the OrthoMabTM protein engineering platform.

    "We are excited to build on the success of the first program and deepen our relationship with the team at Gilead," said Carl Hansen, Ph.D., CEO and President of AbCellera. "We are particularly pleased to see the value created for our partners by quickly integrating the Trianni Mouse® and OrthoMabTM platforms, which we acquired in second half of 2020."

    AbCellera's partners benefit from an operating system designed to support many antibody modalities, unlock new targets, and increase the speed and the probability of success of their therapeutic antibody discovery programs. AbCellera's AI-powered technology stack brings together microfluidics, single cell analysis, machine learning, computation, custom robotics, and automation to compound the power of each step in the discovery process.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    View Full Article Hide Full Article
    • Total revenue of $233 million1 in 2020, up 1,908% year-over-year
    • Total revenue from research fees of $20 million, up 71% year-over-year
    • Total programs under contract of 103, up 72% year-over-year
    • EPS of $0.53 (basic) and $0.45 (diluted) compared to $0.01 loss per share in 2019

    AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the full year 2020 with the following highlights.

    "AbCellera had a breakthrough year, demonstrating strong growth across every area of the business and the effectiveness of our technology and business model through our discovery of the first monoclonal antibody therapy for COVID-19," said Carl Hansen…

    • Total revenue of $233 million1 in 2020, up 1,908% year-over-year
    • Total revenue from research fees of $20 million, up 71% year-over-year
    • Total programs under contract of 103, up 72% year-over-year
    • EPS of $0.53 (basic) and $0.45 (diluted) compared to $0.01 loss per share in 2019

    AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the full year 2020 with the following highlights.

    "AbCellera had a breakthrough year, demonstrating strong growth across every area of the business and the effectiveness of our technology and business model through our discovery of the first monoclonal antibody therapy for COVID-19," said Carl Hansen, Ph.D., President and CEO of AbCellera. "Each program improves our platform, and we continue to invest in new technologies that enhance and expand our capabilities to discover high-quality, potent antibodies for our partners. With our strong cash position, profitability, and cash generation, we are aggressively executing on building our centralized operating system to help bring new antibody therapies to patients faster and more efficiently."

    2020 Business Highlights

    • Strong financial performance led by $233 million in total revenue, including $213 million in milestones and royalties.
    • Generated $119 million in net earnings, up from a $2 million loss in 2019.
    • Expanded partnership business to 103 cumulative programs under contract with 27 partners generating $20 million in research fees (71% growth over $12 million in 2019).
    • Established strong liquidity position with approximately $720 million raised from gross equity financings ($75 million series A2, $90 million convertible note, and $555 million IPO proceeds), and $23 million in positive cash flow from operations to end the year with $594 million in cash and cash equivalents, and $212 million in accrued accounts receivable. AbCellera's strong cash position will be used to build capacity, expand platform capabilities, and pursue business development initiatives.
    • Secured $126 million from the Government of Canada for future infrastructure investments, including CMC and GMP manufacturing capabilities.
    • Acquired Trianni for $90 million to add new capabilities that expand diversity and reduce program timelines by sourcing fully human antibodies from rodents.
    • Acquired the OrthoMab™ bispecific platform to integrate capabilities for engineering bispecific antibodies.
    • Achieved notable COVID-19 program milestones, including bamlanivimab entering clinical trials and receiving authorization in 15 countries across North America, the European Union, the Middle East, and Africa.
    • Announced the appointment of John Montalbano and Peter Thiel to the Board of Directors.

    Key Business Metrics2

    As of December 31, 2020, AbCellera had 103 discovery programs (up 72% from 60 in 2019) that are either completed, in progress, or under contract with 27 partners (up from 22 in 2019). AbCellera has started discovery on a cumulative total of 52 of these programs (up from 43 in 2019).

    Bamlanivimab, being developed by partner Eli Lilly and Company (Lilly), is the first antibody discovered by AbCellera to have reached the clinic and commercial markets. Bamlanivimab is the first monoclonal antibody therapy for COVID-19 in the world to reach human testing and to be authorized for emergency use.

     

     

    Year Ended December 31,

     

     

    Change

     

    Metric

     

    2019

     

     

    2020

     

     

    %

     

    Number of discovery partners

     

     

    22

     

     

     

    27

     

     

     

    23

    %

    Programs under contract, cumulative

     

     

    60

     

     

     

    103

     

     

     

    72

    %

    Program starts, cumulative

     

     

    43

     

     

     

    52

     

     

     

    21

    %

    Programs in the clinic

     

     

    -

     

     

     

    1

     

     

    N/M

     

    Discussion of 2020 Financial Results

     

     

    Year Ended December 31,

     

     

    Change

     

     

     

    2019

     

     

    2020

     

     

    Amount

     

     

    %

     

     

     

    (in thousands, except percentages)

     

    Revenue

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Research fees

     

    $

    11,612

     

     

    $

    19,848

     

     

    $

    8,236

     

     

     

    71

    %

    Milestone payments

     

     

    -

     

     

     

    15,000

     

     

     

    15,000

     

     

    N/A

     

    Royalty revenue

     

     

    -

     

     

     

    198,307

     

     

     

    198,307

     

     

    N/A

     

    Total revenue

     

    $

    11,612

     

     

    $

    233,155

     

     

    $

    221,543

     

     

     

    1908

    %

    • Revenue - Total revenue was $233.2 million in 2020, up 1,908% from $11.6 million in 2019. Research fees increased by $8.2 million, or 71%, as a result of growth in our partnership business. The success of bamlanivimab generated our first milestone payments of $15.0 million and our first royalty revenue of $198.3 million.
    • Royalty fees - Royalty fees to the National Institutes of Health, attributable entirely to royalty payments on bamlanivimab, were $27.1 million as compared to $0 in 2019.
    • Research & Development (R&D) expenses - R&D expenses were $29.4 million in 2020, as compared to $10.1 million in 2019, reflecting investments in the technology platform and increased partnership activity. R&D expenses included non-recurring charges of $4.0 million for IPR&D related to the acquisition of the OrthoMab platform and $4.3 million related to Liability Classified Options in connection with the company's conversion to USD as functional currency.
    • Sales & Marketing (S&M) expenses - S&M expenses were $3.8 million in 2020, as compared to $1.3 million in 2019, driven by an expansion of the team.
    • General & Administrative (G&A) expenses - G&A expenses were $11.9 million in 2020, as compared to $2.7 million in 2019, with the increase driven by investments to support the growth of the company and preparations to be a listed company, as well as non-recurring charges of $1.9 million supporting financing activities.
    • Net Earnings - Net earnings in 2020 were $118.9 million, or $0.53 per share and $0.45 per share on a basic and diluted basis, respectively, as compared to a net loss of $2.2 million, or $0.01 per share on both a basic and diluted basis in 2019.
    • Liquidity - AbCellera ended 2020 with $594.1 million of cash and cash equivalents and $212.3 million in accrued accounts receivable, most of which have subsequently been received. AbCellera ended the year with $2.4 million in debt from a Government of Canada zero interest repayable funding program. The company retired all other debt agreements in the year and incurred a non-recurring $4.2 million expense charge for interest and cancellation fees for early retirement.

    Conference Call and Webcast

    AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Daylight Time (5:00 p.m. Eastern Daylight Time).

    The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera's Investor Relations website at https://investors.abcellera.com. A replay of the webcast will be available through the same link following the conference call.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. To learn more, please visit us at www.abcellera.com.

    Definition of Key Business Metrics

    We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops. For example, as our business matures and to the extent programs are discontinued, we anticipate updating these metrics to reflect such changes.

    Number of discovery partners represents the unique number of partners with whom we have executed partnership contracts. We view this metric as an indication of the competitiveness of our technology stack and our current level of market penetration. The metric also relates to our opportunities to secure programs under contract.

    Programs under contract represent the number of antibody development programs that are under contract for delivery of discovery research activities. A program under contract is counted when a contract is executed with a partner under which we commit to discover antibodies against one selected target. A target is any relevant antigen for which a partner seeks our support in developing binding antibodies. We view this metric as an indication of commercial success and technological competitiveness. It further relates to revenue from technology access fees. The cumulative number of programs under contract with downstream participation is related to our ability to generate future revenue from milestone payments and royalties.

    Program starts represent the number of unique programs under contract for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of our operational capacity to execute on programs under contract. It is also an indication of the selection and initiation of discovery projects by our partners and the resulting near-term potential to earn research fees. Cumulatively, program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties in the mid- to long-term.

    Programs in the clinic represent the count of unique programs for which an Investigational New Drug, or IND, New Animal Drug or Pre-Market Approval, or PMA, application, or equivalents under other regulatory regimes, has been filed based on an antibody that was discovered by us. Where the date of such application is not known to us, the date of the first public announcement of clinical trials will be used instead for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    AbCellera Biologics Inc.

    Condensed Consolidated Statement of Operations

    (Expressed in thousands of U.S. dollars except share and per share data)

     

     

     

     

    2019

     

     

    2020

    Revenue

     

     

     

     

     

     

     

     

     

    Research fees

     

     

    $

    11,612

     

     

    $

    19,848

     

    Milestone payments

     

     

     

    -

     

     

     

    15,000

     

    Royalty revenue

     

     

     

    -

     

     

     

    198,307

     

    Total revenue

     

     

     

    11,612

     

     

     

    233,155

     

    Operating expenses

     

     

     

     

     

     

     

     

     

    Royalty fees

     

     

     

    -

     

     

     

    27,143

     

    Research and development3

     

     

     

    10,113

     

     

     

    29,393

     

    Sales and marketing3

     

     

     

    1,263

     

     

     

    3,842

     

    General and administrative3

     

     

     

    2,749

     

     

     

    11,910

     

    Depreciation and amortization

     

     

     

    1,604

     

     

     

    4,836

     

    Total operating expenses

     

     

     

    15,729

     

     

     

    77,124

     

    Income (loss) from operations

     

     

     

    (4,117

    )

     

     

    156,031

     

    Other (income) expense

     

     

     

     

     

     

     

     

     

    Interest income

     

     

     

    (155

    )

     

     

    (293

    )

    Interest and other expense

     

     

     

    209

     

     

     

    6,511

     

    Foreign exchange (gain) loss

     

     

     

    (186

    )

     

     

    300

     

    Grants and incentives

     

     

     

    (1,774

    )

     

     

    (8,320

    )

    Total other (income) expense

     

     

     

    (1,906

    )

     

     

    (1,802

    )

    Net earnings (loss) before income tax

     

     

     

    (2,211

    )

     

     

    157,833

     

    Provision for income tax

     

     

     

    -

     

     

     

    38,915

     

    Net earnings (loss) and comprehensive income (loss) for the period

     

     

    $

    (2,211

    )

     

    $

    118,918

     

    Net earnings (loss) per share to common shareholders

     

     

     

     

     

     

     

     

     

    Basic

     

     

    $

    (0.01

    )

     

    $

    0.53

     

    Diluted

     

     

    $

    (0.01

    )

     

    $

    0.45

     

    Weighted-average common shares outstanding

     

     

     

     

     

     

     

     

     

    Basic

     

     

     

    151,327,560

     

     

     

    159,195,023

     

    Diluted

     

     

     

    151,327,560

     

     

     

    263,129,765

     

    AbCellera Biologics Inc.

    Condensed Consolidated Balance Sheet

    (Expressed in thousands of U.S. dollars except share data)

     

     

     

    December 31,

    2019

     

     

    December 31,

    2020

    Assets

     

     

     

     

     

     

     

    Current assets

     

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    7,553

     

     

    $

    594,116

    Accounts receivable

     

     

    2,124

     

     

     

    903

    Accrued accounts receivable

     

     

    1,152

     

     

     

    212,336

    Other current assets

     

     

    1,811

     

     

     

    5,970

    Total current assets

     

     

    12,640

     

     

     

    813,325

    Long term assets

     

     

     

     

     

     

     

    Property and equipment, net

     

     

    8,480

     

     

     

    17,923

    Intangible assets

     

     

    -

     

     

     

    115,153

    Goodwill

     

     

    -

     

     

     

    31,500

    Equity investee

     

     

    -

     

     

     

    19,247

    Other long-term assets

     

     

    585

     

     

     

    8,388

    Loans to related parties

     

     

    1,783

     

     

     

    -

    Total long-term assets

     

     

    10,848

     

     

     

    192,211

    Total assets

     

    $

    23,488

     

     

    $

    1,005,536

    Liabilities and shareholders' equity

     

     

     

     

     

     

     

    Current liabilities

     

     

     

     

     

     

     

    Accounts payable and accrued liabilities

     

    $

    2,579

     

     

    $

    20,005

    Current portion of contingent consideration payable

     

     

    -

     

     

     

    13,411

    Income taxes payable

     

     

    -

     

     

     

    36,152

    Accrued royalties payable

     

     

    -

     

     

     

    27,143

    Deferred revenue

     

     

    3,236

     

     

     

    6,589

    Current portion of long-term debt

     

     

    2,080

     

     

     

    190

    Total current liabilities

     

     

    7,895

     

     

     

    103,490

    Long-term liabilities

     

     

     

     

     

     

     

    Operating lease liability

     

     

    2,642

     

     

     

    3,715

    Long-term debt

     

     

    1,363

     

     

     

    2,198

    Deferred revenue and grant funding

     

     

    1,336

     

     

     

    25,894

    Contingent consideration payable

     

     

    -

     

     

     

    9,148

    Deferred tax liability

     

     

    -

     

     

     

    26,161

    Other long-term liabilities

     

     

    -

     

     

     

    4,422

    Total long-term liabilities

     

     

    5,341

     

     

     

    71,538

    Total liabilities

     

    $

    13,236

     

     

    $

    175,028

    Shareholders' equity

     

     

     

     

     

     

     

    Common shares: no par value, unlimited authorized shares at

    December 31, 2019 and 2020: 151,681,382 and 269,497,768

    shares issued and outstanding at December 31, 2019 and 2020

    respectively

     

     

    5,122

     

     

     

    710,387

    Convertible preferred shares unlimited authorized shares at

    December 31, 2019 and 2020: 2,105,264 and nil issued and

    outstanding at December 31, 2019 and 2020 respectively

     

     

    7,546

     

     

     

    -

    Additional paid-in capital

     

     

    2,300

     

     

     

    5,919

    Accumulated earnings (deficit)

     

     

    (4,716

    )

     

     

    114,202

    Total shareholders' equity

     

     

    10,252

     

     

     

    830,508

    Total liabilities and shareholders' equity

     

    $

    23,488

     

     

    $

    1,005,536

     

    AbCellera Biologics Inc.

    Condensed Consolidated Statement of Cash Flows

    (Expressed in thousands of U.S. dollars)

     

     

     

    2019

     

    2020

    Cash flows from operating activities:

     

     

     

     

     

     

     

     

    Net income (loss)

     

    $

    (2,211

    )

     

    $

    118,918

     

    Cash flows from operating activities

     

     

     

     

     

     

     

     

    Depreciation of property and equipment

     

     

    1,604

     

     

     

    2,317

     

    Amortization of intangible assets

     

     

    -

     

     

     

    2,519

     

    Amortization of operating lease right-of-use-assets

     

     

    243

     

     

     

    435

     

    Stock-based compensation

     

     

    890

     

     

     

    8,397

     

    Extinguishment of long-term debt

     

     

    -

     

     

     

    3,700

     

    Accretion and other

     

     

    194

     

     

     

    830

     

    Deferred tax expense

     

     

    -

     

     

     

    2,098

     

    Unrealized foreign exchange gains and losses

     

     

    -

     

     

     

    177

     

    Changes in operating assets and liabilities

     

     

     

     

     

     

     

     

    Accounts and accrued research fees receivable

     

     

    (1,803

    )

     

     

    (5,467

    )

    Accrued royalties receivable

     

     

    -

     

     

     

    (197,553

    )

    Investment tax credit receivable

     

     

    1,593

     

     

     

    -

     

    Income taxes payable

     

     

    -

     

     

     

    36,412

     

    Accounts payable and accrued liabilities

     

     

    150

     

     

     

    6,601

     

    Operating lease liabilities

     

     

    2,784

     

     

     

    (350

    )

    Deferred revenue

     

     

    (6

    )

     

     

    21,810

     

    Accrued royalties payable

     

     

    -

     

     

     

    27,143

     

    Other operating assets and liabilities

     

     

    (744

    )

     

     

    (5,297

    )

    Net cash provided by operating activities

     

     

    2,694

     

     

     

    22,690

     

    Cash flows from investing activities

     

     

     

     

     

     

     

     

    Purchases of property and equipment

     

     

    (3,997

    )

     

     

    (9,673

    )

    Purchase of intangible assets

     

     

    -

     

     

     

    (5,000

    )

    Repayment (issuance) of related party loans

     

     

    (1,783

    )

     

     

    1,783

     

    Acquisition of Trianni

     

     

    -

     

     

     

    (87,643

    )

    Investment in equity investees

     

     

    -

     

     

     

    (19,247

    )

    Net cash used in investing activities

     

     

    (5,780

    )

     

     

    (119,780

    )

    Cash flows from financing activities

     

     

     

     

     

     

     

     

    Repayment of long-term debt

     

     

    (399

    )

     

     

    (19,942

    )

    Proceeds from long-term debt

     

     

    193

     

     

     

    15,490

     

    Proceeds from convertible debentures

     

     

    -

     

     

     

    89,990

     

    Short-term borrowings

     

     

    387

     

     

     

    (387

    )

    Issuance of common shares pursuant to exercise of stock options

     

     

    25

     

     

     

    1,000

     

    Net proceeds from issuance of common shares

     

     

    -

     

     

     

    522,840

     

    Proceeds from issuance of preferred shares - series A1 financing

     

     

    (11

    )

     

     

    -

     

    Proceeds from issuance of preferred shares - series A2 financing

     

     

    -

     

     

     

    74,662

     

    Net cash provided by financing activities

     

    $

    195

     

     

    $

    683,653

     

    Increase (decrease) in cash and cash equivalents

     

     

    (2,891

    )

     

     

    586,563

     

    Cash and cash equivalents, beginning of year

     

     

    10,444

     

     

     

    7,553

     

    Cash and cash equivalents, end of year

     

    $

    7,553

     

     

    $

    594,116

     

     


    1 All financials are reported in USD.

    2 See definitions of Key Business Metrics

    3 Exclusive of depreciation and amortization

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  14. Patients who received bamlanivimab and etesevimab together had an 87% reduction in hospitalizations and death; no patients died who received the therapy

    AbCellera (NASDAQ:ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19. These results mark the second positive Phase 3 trial readout for bamlanivimab and etesevimab together, adding to the growing safety and efficacy data that has resulted in the following key milestones accelerating the adoption of the antibody therapy globally:

    • Emergency

    Patients who received bamlanivimab and etesevimab together had an 87% reduction in hospitalizations and death; no patients died who received the therapy

    AbCellera (NASDAQ:ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19. These results mark the second positive Phase 3 trial readout for bamlanivimab and etesevimab together, adding to the growing safety and efficacy data that has resulted in the following key milestones accelerating the adoption of the antibody therapy globally:

    • Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA).
    • Expanded access in the European Union through the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).
    • Recommended use by the National Institutes of Health through its COVID-19 Treatment Guidelines.
    • Delivery of up to 1.2 million doses to the U.S. government through a purchase agreement with Lilly.

    "Across the two Phase 3 cohorts of the BLAZE-1 study, there were no deaths in patients who received bamlanivimab together with etesevimab, as compared to 14 deaths in patients receiving placebo, 13 of which were categorized as COVID-19-related," said Carl Hansen, Ph.D., CEO and President of AbCellera. "No COVID-19-related deaths have been observed across the thousands of patients who have been treated with bamlanivimab alone or together with etesevimab in clinical trials. These antibody therapies can be powerful tools in keeping COVID-19 patients out of the hospital and preventing death."

    The results from this new randomized, double-blind, placebo-controlled Phase 3 BLAZE-1 study provide additional efficacy and safety data that support the use of the dose recently granted both EUA by the U.S. FDA, and a positive scientific opinion by the EMA CHMP.

    Key details from the study, which included 769 high-risk patients, aged 12 and older with mild to moderate COVID-19 (therapy: n=511; placebo: n=258), are as follows:

    • 87% reduction in COVID-19-related hospitalizations and deaths versus placebo (p<0.0001).
    • No COVID-19-related deaths in the treatment group. All deaths occurred in patients treated with the placebo.
    • A safety profile consistent with those observed from other Phase 1, Phase 2, and Phase 3 trials evaluating these antibodies.

    Details regarding Lilly's BLAZE-1 trial can be found here.

    Bamlanivimab alone and together with etesevimab are authorized under special/emergency pathways, in the context of the pandemic, in the U.S. and the European Union. In addition, bamlanivimab alone is authorized for emergency use in Canada, Panama, Kuwait, the UAE, Israel, Rwanda, Morocco, and numerous other countries. Through Lilly's work with the Bill & Melinda Gates Foundation, Lilly is providing doses of bamlanivimab free of charge in Rwanda and Morocco.

    About AbCellera's Response to COVID-19

    Bamlanivimab was developed from an antibody that was discovered from the blood of a recovered COVID-19 patient using AbCellera's pandemic response platform, in partnership with the Vaccine Research Center (VRC) at National Institute of Allergy and Infectious Diseases (NIAID). Within one week of receiving the sample, AbCellera screened over five million antibody-producing cells to identify and isolate approximately 500 unique antibodies that bind to SARS-CoV-2, the virus that causes COVID-19. The binding antibodies were then tested by AbCellera, the VRC, and Lilly to find those most effective in neutralizing the virus. Bamlanivimab was selected as the lead candidate from this group of antibodies, and was the first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials in North America. Bamlanivimab was the first monoclonal antibody to receive EUA from the FDA and is currently being assessed in several clinical trials alone and together with other antibodies.

    AbCellera's pandemic response capabilities were developed over the past three years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen. AbCellera's ongoing efforts to respond to the pandemic have identified more than 2,300 unique anti-SARS-CoV-2 human antibodies from multiple patient samples. These antibodies are in various stages of testing by AbCellera and its partners.

    About Bamlanivimab

    Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at NIAID VRC. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

    Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  15. Positive European Union (EU)-level scientific opinion provides a pathway for more EU countries to access the antibodies to treat COVID-19 before formal marketing authorizations are granted

    AbCellera (NASDAQ:ABCL) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab. The opinion advises bamlanivimab alone and bamlanivimab administered together with etesevimab can be used for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at high risk of progressing to severe COVID-19. The CHMP…

    Positive European Union (EU)-level scientific opinion provides a pathway for more EU countries to access the antibodies to treat COVID-19 before formal marketing authorizations are granted

    AbCellera (NASDAQ:ABCL) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab. The opinion advises bamlanivimab alone and bamlanivimab administered together with etesevimab can be used for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at high risk of progressing to severe COVID-19. The CHMP recommendation provides a harmonized, EU-level opinion on the efficacy, quality, and safety of the antibodies, which can be used by EU member states when making decisions on the possible use of the therapies at a national level prior to market authorization.

    "Bamlanivimab has been used to treat hundreds of thousands of patients globally, and its impact continues to grow as the use of COVID-19 antibody therapies accelerates," said Carl Hansen, Ph.D., CEO and President of AbCellera. "Several EU countries have authorized bamlanivimab, and the EMA's CHMP recommendation provides a mechanism for more EU countries to quickly access these antibodies to treat patients in need."

    The EMA reviewed Phase 2 and Phase 3 results from Eli Lilly and Company's (Lilly) BLAZE-1 trial to support the CHMP opinion. Results from BLAZE-1 demonstrated bamlanivimab alone reduced viral load and rates of symptoms and also reduced hospitalization by approximately 70%, and bamlanivimab and etesevimab together reduced the risk of COVID-19 hospitalizations and death by 70% in non-hospitalized high-risk patients with mild to moderate COVID-19. Details regarding the CHMP opinion and Lilly's plans to make COVID-19 therapies broadly available to patients can be found here.

    Bamlanivimab has been authorized in more than 10 countries, and bamlanivimab together with etesevimab received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) on February 9, 2021. The EUA was followed by a $210 million purchase agreement for Lilly to provide 100,000 doses of bamlanivimab and etesevimab to the U.S. government through to March 31, 2021. The U.S. government will have the option to purchase up to an additional 1,100,000 doses through November 25, 2021. This purchase agreement is in addition to the 1,450,000 doses of bamlanivimab alone that the US government previously committed to purchase: to date, more than 1 million doses have been delivered, and Lilly has agreed to deliver 450,000 additional doses by March 31, 2021. AbCellera is eligible to receive royalties in the low- to mid-teens for aggregate sales below $125.0 million and mid-teens to mid-twenties on aggregate sales above $125.0 million. Sales of bamlanivimab in 2020 were $871 million.

    About AbCellera's Response to COVID-19

    Bamlanivimab was developed from an antibody that was discovered from the blood of a recovered COVID-19 patient using AbCellera's pandemic response platform, in partnership with the Vaccine Research Center (VRC) at National Institute of Allergy and Infectious Diseases (NIAID). Within one week of receiving the sample, AbCellera screened over five million antibody-producing cells to identify and isolate approximately 500 unique antibodies that bind to SARS-CoV-2, the virus that causes COVID-19. The binding antibodies were then tested by AbCellera, the VRC, and Lilly to find those most effective in neutralizing the virus. Bamlanivimab was selected as the lead candidate from this group of antibodies, and was the first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials in North America. Bamlanivimab was the first monoclonal antibody to receive EUA from the FDA and is currently being assessed in several clinical trials alone and together with other antibodies.

    AbCellera's pandemic response capabilities were developed over the past three years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen. AbCellera's ongoing efforts to respond to the pandemic have identified more than 2,300 unique anti-SARS-CoV-2 human antibodies from multiple patient samples. These antibodies are in various stages of testing by AbCellera and its partners.

    About Bamlanivimab

    Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at NIAID VRC. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

    Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  16. AbCellera (NASDAQ:ABCL) will present at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:20 p.m. Pacific Time.

    A live audio webcast may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay of the webcast will be available through the same link following the presentation.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle…

    AbCellera (NASDAQ:ABCL) will present at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:20 p.m. Pacific Time.

    A live audio webcast may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay of the webcast will be available through the same link following the presentation.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. To learn more, please visit us at www.abcellera.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    View Full Article Hide Full Article
  17. AbCellera (NASDAQ:ABCL) announced today that Ester Falconer, Ph.D., has been appointed as Chief Technology Officer (CTO), effective January 28, 2021.

    As CTO, Dr. Falconer will lead AbCellera's long-term strategy in the development, aggregation, and integration of technologies that improve the speed and success of therapeutic antibody discovery from target to investigational new drug application submission.

    "Dr. Falconer is an accomplished and creative technologist whose contributions have been indispensable to AbCellera's success. She is also one of our strongest leaders and an effective mentor with a proven ability to build high-performing teams," said Carl Hansen, Ph.D., CEO of AbCellera. "We welcome her to the executive team and are fortunate…

    AbCellera (NASDAQ:ABCL) announced today that Ester Falconer, Ph.D., has been appointed as Chief Technology Officer (CTO), effective January 28, 2021.

    As CTO, Dr. Falconer will lead AbCellera's long-term strategy in the development, aggregation, and integration of technologies that improve the speed and success of therapeutic antibody discovery from target to investigational new drug application submission.

    "Dr. Falconer is an accomplished and creative technologist whose contributions have been indispensable to AbCellera's success. She is also one of our strongest leaders and an effective mentor with a proven ability to build high-performing teams," said Carl Hansen, Ph.D., CEO of AbCellera. "We welcome her to the executive team and are fortunate to have her leading our platform development."

    Prior to her promotion to CTO, Dr. Falconer was the Head of Research and Development, overseeing technology development in genomics, microfluidics, biochemistry, protein engineering, data sciences, and machine learning. She led the development of AbCellera's Pandemic Preparedness Platform (P3) program and its deployment to combat COVID-19. This resulted in the discovery and development of bamlanivimab, the first monoclonal antibody therapy to receive Emergency Use Authorization (EUA) by U.S. Food and Drug Administration (FDA) to treat COVID-19, which has been authorized in more than eight countries and used to treat more than 125,000 patients.

    "AbCellera is an exceptional company of talented people driving incredible technology advances," said Dr. Falconer. "I am excited and honoured to continue developing our platform with this team, in our overall mission to power drug development for partners and ultimately for patients."

    Dr. Falconer joined AbCellera in 2015 as Senior Research Scientist, and subsequently advanced to become Group Leader of Molecular Biology and Antibody Expression in 2017, and Head of Research and Development in 2019. She earned a Ph.D. in genetics and cell biology from the University of British Columbia in 2005. Dr. Falconer completed a postdoctoral fellowship in stem cell biology and cancer research in 2015 that led to development of single cell technologies to map genomic rearrangements, applicable to genomic instability, genome assembly, and long-range haplotyping.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  18. Bamlanivimab now authorized in two antibody therapy regimens to treat COVID-19 in patients at high risk for hospitalization

    FDA authorizes new protocols for infusion of bamlanivimab in as few as 16 minutes

    AbCellera (NASDAQ:ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), administered with a second Lilly antibody, etesevimab (LY-CoV016) 1400 mg, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization. New protocols enable front-line clinicians to…

    Bamlanivimab now authorized in two antibody therapy regimens to treat COVID-19 in patients at high risk for hospitalization

    FDA authorizes new protocols for infusion of bamlanivimab in as few as 16 minutes

    AbCellera (NASDAQ:ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), administered with a second Lilly antibody, etesevimab (LY-CoV016) 1400 mg, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization. New protocols enable front-line clinicians to administer bamlanivimab alone and bamlanivimab and etesevimab together in as few as 16 minutes and 21 minutes, respectively.

    "The data show that bamlanivimab alone and bamlanivimab and etesevimab together are effective at reducing hospitalizations in high-risk COVID-19 patients, with consistent and similar efficacy across studies," said Carl Hansen, Ph.D., CEO and President of AbCellera. "With this EUA for bamlanivimab and etesevimab together, there are more treatment options for patients at high risk for hospitalization and another layer of protection against the emergence of new viral variants."

    The EUA is based on Phase 3 data from the BLAZE-1 trial, which were announced on January 26, 2021. In that study of more than 1,000 COVID-19 patients, those who received bamlanivimab and etesevimab together had a reduction in hospitalizations of 70% and none died. Lilly plans to manufacture more than 250,000 doses of the bamlanivimab and etesevimab therapy throughout Q1 2021, and up to a million doses by mid-2021. Details regarding the EUA and Lilly's plans to make COVID-19 therapies broadly available to patients can be found here.

    About AbCellera's Response to COVID-19

    Bamlanivimab was developed from an antibody that was discovered from the blood of a recovered COVID-19 patient using AbCellera's pandemic response platform, in partnership with the Vaccine Research Center (VRC) at National Institute of Allergy and Infectious Diseases (NIAID). Within one week of receiving the sample, AbCellera screened over five million antibody-producing cells to identify and isolate approximately 500 unique antibodies that bind to SARS-CoV-2, the virus that causes COVID-19. The binding antibodies were then tested by AbCellera, the VRC, and Lilly to find those most effective in neutralizing the virus. Bamlanivimab was selected as the lead candidate from this group of antibodies, and was the first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials in North America. Bamlanivimab was the first monoclonal antibody to receive EUA from the FDA and is currently being assessed in several clinical trials alone and together with other antibodies.

    AbCellera's pandemic response capabilities were developed over the past two years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen. AbCellera's ongoing efforts to respond to the pandemic have identified more than 2,300 unique anti-SARS-CoV-2 human antibodies from multiple patient samples. These antibodies are in various stages of testing by AbCellera and its partners.

    About Bamlanivimab

    Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at NIAID VRC. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

    Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    Approved for Public Release. Distribution Unlimited.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  19. AbCellera (NASDAQ:ABCL) will announce its fourth-quarter and full-year 2020 financial results on Monday, March 29, 2021 after the U.S. stock markets close and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

    The live webcast of the earnings conference call can be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers…

    AbCellera (NASDAQ:ABCL) will announce its fourth-quarter and full-year 2020 financial results on Monday, March 29, 2021 after the U.S. stock markets close and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

    The live webcast of the earnings conference call can be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    View Full Article Hide Full Article
  20. Launch of Catalio Credit Demonstrates Continued Growth & Evolution of Catalio Platform

    Catalio Capital Management, LP (Catalio), a multi-strategy life sciences investment firm, has today announced the launch of their Credit Opportunities strategy to expand the scope of the firm's investments across the biomedical technology industry and meet the growing demand for non-dilutive growth capital within the sector.

    The Catalio Credit Opportunities strategy seeks to provide senior-secured structured credit to breakthrough biomedical companies, targeting well-capitalized, pre-cashflow businesses with significant support from institutional investors. The strategy will be led by Co-Portfolio Managers John Henry Iucker and Robert Snyder. Mr. Iucker…

    Launch of Catalio Credit Demonstrates Continued Growth & Evolution of Catalio Platform

    Catalio Capital Management, LP (Catalio), a multi-strategy life sciences investment firm, has today announced the launch of their Credit Opportunities strategy to expand the scope of the firm's investments across the biomedical technology industry and meet the growing demand for non-dilutive growth capital within the sector.

    The Catalio Credit Opportunities strategy seeks to provide senior-secured structured credit to breakthrough biomedical companies, targeting well-capitalized, pre-cashflow businesses with significant support from institutional investors. The strategy will be led by Co-Portfolio Managers John Henry Iucker and Robert Snyder. Mr. Iucker and Mr. Snyder both joined Catalio from Brown Advisory, an asset management firm with over $100B in AUM, where they played an instrumental role in building Brown's credit platform.

    In addition to Mr. Iucker and Mr. Snyder, Joshua Samuelson will be joining the Investment Committee of the Credit Opportunities strategy. Mr. Samuelson was a Co-Founder of PointState Capital, a long/short equity and macro-focused fund. At PointState, Mr. Samuelson served as President and managed a diverse portfolio across multiple asset classes until his retirement at the end of 2019. Prior to his time at PointState, he was a Portfolio Manager at Duquesne Capital Management and Soros Fund Management, where, over the course of his career, he focused on convertible bonds, equities and credit.

    Catalio also announced today the appointment of Brandon Matz as the firm's Head of Marketing & Investor Relations. Mr. Matz is joining Catalio from York Capital Management, a global alternative investment firm with approximately $20B in AUM.

    The launch of the Catalio Credit Opportunities strategy is the latest milestone of many for Catalio, which has grown exponentially since its inception last year. It is now a leading multi-strategy investment firm, with over $450 million in committed capital between both private and public equity strategies.

    George Petrocheilos and Dr. Jacob Vogelstein, Catalio's Co-Founders & Co-Managing Partners said: "We are delighted to welcome John Henry, Rob, Josh and Brandon to Catalio. The life sciences industry continues to offer significant opportunities for investment, and these latest additions to our team will further augment our platform and help our transformative biomedical technology companies to bring their innovations to market.''

    Since inception, Catalio has invested in more than 20 prominent high-growth life science companies including AbCellera (NASDAQ:ABCL), COMPASS Pathways (NASDAQ:CMPS) and Thrive Earlier Detection (recently acquired by EXACT Sciences (NASDAQ: EXAS)). The firm closed its oversubscribed second venture fund, Catalio Nexus II, at its hard cap of $100 million in September 2020 and recently announced the launch of HealthCor Catalio Acquisition Corp. (NASDAQ:HCAQ), a special purpose acquisition company, targeting acquisitions in the healthcare industry.

    About Catalio Capital Management L.P.

    Catalio Capital Management, L.P., is a multi-strategy life sciences investment firm that focuses on breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics and data-driven insights. Catalio's General Partnership includes over 25 world-renowned scientists with extensive academic bona fides who have also started several successful companies based on their research. Catalio has offices in New York, Baltimore, and Washington, DC. For more information, visit www.cataliocapital.com.

    View Full Article Hide Full Article
  21. Bamlanivimab's powerful neutralization of the virus responsible for COVID-19 provides therapeutic backbone for new therapies to expand protection against viral variants

    AbCellera (NASDAQ:ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), will be evaluated together with VIR-7831, an antibody developed by Vir Biotechnology, Inc. and GlaxoSmithKline, as a potential COVID-19 therapy in low-risk patients with mild to moderate COVID-19. Bamlanivimab is currently a component in all Lilly's antibody-based COVID-19 therapies, which include bamlanivimab alone, and bamlanivimab and etesevimab together. Lilly will expand the ongoing BLAZE-4 trials to evaluate…

    Bamlanivimab's powerful neutralization of the virus responsible for COVID-19 provides therapeutic backbone for new therapies to expand protection against viral variants

    AbCellera (NASDAQ:ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), will be evaluated together with VIR-7831, an antibody developed by Vir Biotechnology, Inc. and GlaxoSmithKline, as a potential COVID-19 therapy in low-risk patients with mild to moderate COVID-19. Bamlanivimab is currently a component in all Lilly's antibody-based COVID-19 therapies, which include bamlanivimab alone, and bamlanivimab and etesevimab together. Lilly will expand the ongoing BLAZE-4 trials to evaluate bamlanivimab together with VIR-7831. Details about Lilly's trial are available here.

    Bamlanivimab is a human antibody that reduces the risk of contracting COVID-19 by up to 80% in people exposed to the virus, prevents COVID-19 related deaths, and reduces hospitalizations by 70%-80% in patients recently diagnosed with mild to moderate COVID-19. Bamlanivimab, which was discovered by AbCellera in March 2020 and reached human clinical trials 90 days later, was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) in November 2020.

    "To date, more than 100,000 patients have received bamlanivimab, and the data from clinical trials show its use saves lives and prevents hospitalizations," said Carl Hansen, Ph.D., CEO and President of AbCellera. "Bamlanivimab alone remains an important antibody therapy, and we are pleased it will be evaluated with VIR-7831 to potentially expand the impact of antibody therapies on viral variants."

    To date, bamlanivimab 700 mg has been authorized in the United States, Canada, Germany, Israel, Hungary, United Arab Emirates, Kuwait, Saudia Arabia, and Panama to treat mild to moderate COVID-19 in high-risk patients.

    About AbCellera's Response to COVID-19

    Bamlanivimab was developed from an antibody that was discovered from the blood of a recovered COVID-19 patient using AbCellera's pandemic response platform, in partnership with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID). Within one week of receiving the sample, AbCellera screened over five million antibody-producing cells to identify and isolate approximately 500 unique antibodies that bind to SARS-CoV-2, the virus that causes COVID-19. The binding antibodies were then tested by AbCellera, the VRC, and Lilly to find those most effective in neutralizing the virus. Bamlanivimab was selected as the lead candidate from this group of antibodies and was the first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials in North America. Bamlanivimab was the first monoclonal antibody to receive EUA from the U.S. FDA and is currently being assessed in several clinical trials alone and together with other antibodies.

    AbCellera's pandemic response capabilities were developed over the past two years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen. AbCellera's ongoing efforts to respond to the pandemic have identified more than 2,300 unique anti-SARS-CoV-2 human antibodies from multiple patient samples. These antibodies are in various stages of testing by AbCellera and its partners.

    About Bamlanivimab

    Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at NIAID VRC. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

    Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

    Bamlanivimab is authorized in the U.S. for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    View Full Article Hide Full Article
  22. AbCellera (NASDAQ:ABCL) today announced that bamlanivimab (LY-CoV555) 2800 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 2800 mg (LY-CoV16) together significantly reduced COVID-19 related hospitalizations and deaths (collectively, "events") in more than 1,000 high-risk patients recently diagnosed with COVID-19.

    Key details from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 2/3 study are as follows:

    • The trial met its primary endpoint and key secondary endpoints with high statistical significance;
    • Bamlanivimab and etesevimab together reduced COVID-19 events by 70% versus placebo (p=0.0004); and
    • All deaths occurred in patients taking the placebo. No deaths occurred…

    AbCellera (NASDAQ:ABCL) today announced that bamlanivimab (LY-CoV555) 2800 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 2800 mg (LY-CoV16) together significantly reduced COVID-19 related hospitalizations and deaths (collectively, "events") in more than 1,000 high-risk patients recently diagnosed with COVID-19.

    Key details from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 2/3 study are as follows:

    • The trial met its primary endpoint and key secondary endpoints with high statistical significance;
    • Bamlanivimab and etesevimab together reduced COVID-19 events by 70% versus placebo (p=0.0004); and
    • All deaths occurred in patients taking the placebo. No deaths occurred in patients taking bamlanivimab and etesevimab together.

    "The data from the BLAZE-1 study are both compelling and entirely consistent with the interim data that were the basis for Emergency Use Authorization of bamlanivimab. They show that if given early in infection, antibody therapy can keep most patients out of hospitals and can save lives," said Carl Hansen, Ph.D., CEO and President of AbCellera. "Together with the recent data reported from the BLAZE-2 trial, no COVID-19 deaths have been observed in these treatment arms in patients treated with bamlanivimab, either alone, or together with etesevimab. It is mission critical that these treatments be made available to high-risk patients as soon as possible."

    Interim data from Lilly's Phase 2 BLAZE-1 COVID-19 trial were reported on September 16, 2020 and were the basis for authorizations of bamlanivimab 700 mg in the United States, Canada, and Europe for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization.

    Additional details about Lilly's trial are available here.

    About AbCellera's Response to COVID-19

    Bamlanivimab was developed from an antibody that was discovered from the blood of a recovered COVID-19 patient using AbCellera's pandemic response platform, in partnership with the Vaccine Research Center (VRC) at NIAID. Within one week of receiving the sample, AbCellera screened over five million antibody-producing cells to identify and isolate approximately 500 unique antibodies that bind to SARS-CoV-2, the virus that causes COVID-19. The binding antibodies were then tested by AbCellera, the VRC, and Lilly to find those most effective in neutralizing the virus. Bamlanivimab was selected as the lead candidate from this group of antibodies, and was the first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials in North America. Bamlanivimab was the first monoclonal antibody to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and is currently being assessed in several clinical trials as both a monotherapy and in combination with other antibodies.

    AbCellera's pandemic response capabilities were developed over the past two years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen. AbCellera's ongoing efforts to respond to the pandemic have identified more than 2,300 unique anti-SARS-CoV-2 human antibodies from multiple patient samples. These antibodies are in various stages of testing by AbCellera and its partners.

    About Bamlanivimab

    Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at NIAID VRC. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

    Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

    Bamlanivimab is authorized in the U.S. for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  23. AbCellera (NASDAQ:ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. Lilly's Phase 3 BLAZE-2 COVID-19 prevention trial was conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN).

    Key details from the BLAZE-2 study are as follows:

    • Participants were grouped based on their COVID-19 status at baseline: 965 COVID-19 negative participants (299 residents and 666 staff) were in the prevention group, and…

    AbCellera (NASDAQ:ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. Lilly's Phase 3 BLAZE-2 COVID-19 prevention trial was conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN).

    Key details from the BLAZE-2 study are as follows:

    • Participants were grouped based on their COVID-19 status at baseline: 965 COVID-19 negative participants (299 residents and 666 staff) were in the prevention group, and 132 COVID-19 positive participants (41 residents and 91 staff) were in the treatment group;
    • Participants in each group were randomized to receive either 4,200 mg of bamlanivimab or placebo;
    • Serious adverse events were reported at a similar frequency in both placebo and bamlanivimab groups, consistent with previous safety observations in Phase 1 and Phase 2 trials;
    • Bamlanivimab reduced the risk of contracting COVID-19 by up to 80% in residents versus placebo (odds ratio 0.20; p=0.00026); and
    • All deaths attributed to COVID-19 occurred in residents receiving the placebo. There were no COVID-19-related deaths of participants receiving bamlanivimab.

    "The data from the Phase 3 BLAZE-2 trial show that bamlanivimab provides effective protection against COVID-19 infection, with the greatest impact on the most vulnerable patients," said Carl Hansen, Ph.D., CEO and President of AbCellera. "Furthermore, data obtained from the treatment group are completely consistent with what was observed in the BLAZE-1 trial. This reinforces the importance of efforts to ensure high-risk patients get access to antibody therapy early in COVID-19 infection. We believe bamlanivimab can save lives if delivered early."

    Additional details about Lilly's trial are available here.

    About AbCellera's Response to COVID-19

    Bamlanivimab was developed from an antibody that was discovered from the blood of a recovered COVID-19 patient using AbCellera's pandemic response platform, in partnership with the Vaccine Research Center (VRC) at NIAID. Within one week of receiving the sample, AbCellera screened over five million antibody-producing cells to identify and isolate approximately 500 unique antibodies that bind to SARS-CoV-2, the virus that causes COVID-19. The binding antibodies were then tested by AbCellera, the VRC, and Lilly to find those most effective in neutralizing the virus. Bamlanivimab was selected as the lead candidate from this group of antibodies, and was the first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials in North America. Bamlanivimab was the first monoclonal antibody to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and is currently being assessed in several clinical trials as both a monotherapy and in combination with other antibodies.

    AbCellera's pandemic response capabilities were developed over the past two years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen. AbCellera's ongoing efforts to respond to the pandemic have identified more than 2,300 unique anti-SARS-CoV-2 human antibodies from multiple patient samples. These antibodies are in various stages of testing by AbCellera and its partners.

    About Bamlanivimab

    Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at NIAID VRC. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

    Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

    Bamlanivimab 700 mg is authorized in the U.S. for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    Source: AbCellera Biologics Inc.

    View Full Article Hide Full Article
  24. The Trianni Mouse®, AbCellera's technology for generating large databases of human antibodies for drug discovery programs, is granted United States patent

    AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology. AbCellera uses the transgenic animal technology to generate fully human monoclonal antibodies for its drug discovery programs with biotech and pharma partners. The United States Patent and Trademark Office (USPTO) issued patent no. 10,881,084 titled "Transgenic Animals and Methods of Use" to Trianni, Inc. (Trianni), an AbCellera Company.

    "This patent is…

    The Trianni Mouse®, AbCellera's technology for generating large databases of human antibodies for drug discovery programs, is granted United States patent

    AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology. AbCellera uses the transgenic animal technology to generate fully human monoclonal antibodies for its drug discovery programs with biotech and pharma partners. The United States Patent and Trademark Office (USPTO) issued patent no. 10,881,084 titled "Transgenic Animals and Methods of Use" to Trianni, Inc. (Trianni), an AbCellera Company.

    "This patent is an important addition to our IP portfolio, providing protection to our proprietary technology in the U.S.," said Carl Hansen, Ph.D., CEO of AbCellera and Trianni. "By generating fully human antibodies in the first step of the discovery process, we're able to increase the speed and efficiency of our partners' programs to develop therapeutic antibodies."

    Trianni's genetic engineering technology, which AbCellera acquired in November 2020, is an advanced transgenic platform for developing mice that produce human antibodies. The flagship Trianni Mouse® platform was designed to maximize immune responses, increase antibody diversity, and preserve natural maturation of fully human antibodies. It is also a core platform for quickly developing increasingly powerful transgenic mouse technologies for use in partner programs.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

    About Trianni, Inc.

    Trianni, an AbCellera company, specializes in antibody discovery technology using transgenic mice. Trianni's lead technology, the Trianni Mouse®, is a next-generation platform enabling efficient generation of diverse, fully human monoclonal antibodies. The Trianni transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic engineering technology. Additional information about Trianni is available at www.trianni.com.

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    View Full Article Hide Full Article
  25. adMare BioInnovations is Canada's Global Life Sciences Venture, building the Canadian life sciences industry from sea to sea. (CNW Group/adMare BioInnovations)

    Abdera is a precision oncology company developing novel next-generation targeted alpha therapies for patients with relapsed, refractory and metastatic cancers. (CNW Group/adMare BioInnovations)

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. (CNW Group/adMare BioInnovations)

    Abdera to accelerate the development of targeted radiotherapies to fight hard-to-treat cancer

    VANCOUVER, BC, Jan. 14, 2021 /CNW/ - adMare BioInnovations, Canada's global life sciences venture, is pleased to announce the launch of Abdera Therapeutics Inc. (Abdera) with founding partner, AbCellera (NASDAQ:ABCL). Abdera is a precision oncology company developing novel next-generation targeted alpha therapies (TATs) for patients with relapsed, refractory and metastatic cancers. The seed financing of Abdera includes a total commitment of CAD $8 million. Abdera will leverage AbCellera's antibody discovery platform to develop antibody-based TATs against nine (9) clinically-validated oncology targets. Under the agreement, AbCellera will receive…

    adMare BioInnovations is Canada's Global Life Sciences Venture, building the Canadian life sciences industry from sea to sea. (CNW Group/adMare BioInnovations)

    Abdera is a precision oncology company developing novel next-generation targeted alpha therapies for patients with relapsed, refractory and metastatic cancers. (CNW Group/adMare BioInnovations)

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. (CNW Group/adMare BioInnovations)

    Abdera to accelerate the development of targeted radiotherapies to fight hard-to-treat cancer

    VANCOUVER, BC, Jan. 14, 2021 /CNW/ - adMare BioInnovations, Canada's global life sciences venture, is pleased to announce the launch of Abdera Therapeutics Inc. (Abdera) with founding partner, AbCellera (NASDAQ:ABCL). Abdera is a precision oncology company developing novel next-generation targeted alpha therapies (TATs) for patients with relapsed, refractory and metastatic cancers. The seed financing of Abdera includes a total commitment of CAD $8 million. Abdera will leverage AbCellera's antibody discovery platform to develop antibody-based TATs against nine (9) clinically-validated oncology targets. Under the agreement, AbCellera will receive equity and research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products.

    "The adMare team is proud to launch our third new well-funded company this fiscal year. Canada has already demonstrated its global leadership in radioisotope-based healthcare technologies, and we have unique infrastructure that provides a competitive advantage," said Gordon C. McCauley, adMare President and CEO. "Our team has been working on the substance of Abdera for three years, and now we are ready to show why Canada and Abdera will become a world leader in developing related novel therapeutics."

    TATs are a potentially transformative new class of drugs based on therapeutic antibodies armed with high-energy radioisotopes that emit alpha particles to selectively destroy cancer tumor cells. Abdera's core technology comprises a proprietary and modular radioimmunoconjugate platform that is optimized to selectively deliver radioisotopes, including Actinium-225. Abdera will use its platform to enable the rapid development of a broad range of safe and efficacious therapies that will serve patients with limited treatment options.

    "Our antibody discovery operating system provides a powerful vehicle for quick and efficient venture creation," said Carl Hansen, Ph.D., CEO and President of AbCellera. "By partnering with AbCellera, the Abdera team can focus on developing their proprietary technology and creating new therapies for patients with cancer."

    Abdera's founding management team is comprised of leading biopharmaceutical industry executives, including adMare Venture Partner Dr. Lana Janes, who will act as the company's Interim Chief Executive Officer. Dr. Janes brings over 20 years of global pharmaceutical development expertise that spans the full life cycle of therapeutic product development. She is joined by Dr. Michael Abrams, one of Canada's most successful scientist entrepreneurs, as Chief Scientific Officer, and Dr. Adam Judge as Senior Vice President, Biology; and will be supported by adMare's deep research and development and business teams.

    "In building Abdera, we identified the most promising early-stage technologies for this high-potential area of drug development together with a proven executive team," said Dr. Lana Janes. "With Abdera's deep biologics and radiotherapeutics commercial experience, our founding partner AbCellera's leading antibody discovery platform, and the full force of the adMare enterprise behind us, we look forward to identifying therapies for patients without treatment options today."

    About adMare BioInnovations

    adMare BioInnovations is Canada's global life sciences venture, building the Canadian life sciences industry from sea to sea. We do this by sourcing therapeutically and commercially promising research from leading academic and biotech partners to create new companies of scale, providing specialized expertise, infrastructure, and capital to help existing companies scale up, and driving the growth of those companies into Canadian anchors by training the next generation of highly qualified personnel. adMare's ~20 portfolio companies have attracted more than $1.15B of investment, and have a combined worth of over $2.3B. admarebio.com

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. www.abcellera.com

    AbCellera Forward-looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    SOURCE adMare BioInnovations

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2021/14/c6865.html

    View Full Article Hide Full Article
  26. TORONTO, Jan. 5, 2021 /CNW/ - While the US initial public offering (IPO) and special purpose acquisition corporation (SPAC) market experienced an unprecedent boom in 2020, Canadian IPO market continued to struggle with mixed results.

    77 IPOs including capital pool companies (CPCs) and SPACs were completed in 2020 on four Canadian stock exchanges, raising $5.55 billion in aggregate gross proceeds, or excluding CPCs and SPACs, 43 IPOs for $4.85 billion.

    The 2020 IPO numbers represent a decrease of 29% in total number of IPOs and an increase of 116% in total amount or, excluding CPC/SPAC IPOs, a decrease of 7% in total IPO number and an increase of 605% in total amount from 2019.

    Excluding CPC/SPAC IPOs, CSE continues to lead all Canadian exchanges with 25 IPOs (58%), comparing to 31 IPOs (67%) in 2019. 

    Mining issuers led all sectors with 23 IPOs for $324 million, accounting for 53% and 7% of the total number of Non-CPC/SPAC IPOs and total amount respectively.

    4 Private Equity (PE) and 2 Venture Capital (VC) backed IPOs dominated the total amount, raising $3,395 million and $144 million respectively, or $3,539 million in aggregate, representing 64% of total IPO amount or 73% of total Non-CPC/SPAC IPO amount.

    2020 IPO Breakdown by Exchanges (Non-CPC/SPAC)

    • CSE – 25 IPOs for $43 million (25 IPOs for $43 million)
    • TSX – 11 IPO for $4,726 million (10 IPOs for $4,460 million)
    • TSX Venture Exchange – 39 IPOs for $364 million (8 IPOs for $350 million)
    • NEO – 2 IPOs for $421 million (nil)

    2020 Canadian IPOs League Table – Top 8 Law Firms (by # IPOs only)

    All IPO Ranking (#, $total IPO value)

    1. Miller Thomson LLP (13, $17M)
    2. Blake, Cassels & Graydon LLP (11, $1,549M)
    3. DuMoulin Black LLP (8, $17M)
    4. Cassels Brock & Blackwell LLP (7, $38M)
    5. Harper Grey LLP (7, $10M)
    6. MLT Aikins LLP (7, $5M)
    7. Peterson McVicar LLP (7, $2M)
    8. Borden Ladner Gervais LLP (6, $12M)

    Non-CPC/SPAC IPO Ranking (#, $total IPO value)

    1. Blake, Cassels & Graydon LLP (8, $861M)
    2. Miller Thomson LLP (7, $16M)
    3. Stikeman Elliott LLP (5, $2,165M)
    4. DuMoulin Black LLP (5, $16M)
    5. Harper Grey LLP (5, $10M)
    6. Cassels Brock & Blackwell LLP (4, $37M)
    7. Vantage Law Corporation (4, $6M)
    8. Lotz & Company (4, $2M)

    2020 Canadian IPOs League Table – Top 13 Underwriters (by # IPOs Only)

    All IPO Ranking (#, $total IPO value)

    1. Canaccord Genuity Corp. (26, $2,535M)
    2. Haywood Securities Inc. (24, $ 25M)
    3. BMO Nesbitt Burns Inc. (12, $ 4,651M)
    4. Scotia Capital Inc. (9, $4,349M)
    5. CIBC World Markets Inc. (8, $4,372M)
    6. Leede Jones Gable Inc. (8, $12M)
    7. Raymond James Ltd. (7, $4,053M)
    8. TD Securities Inc. (7, $4,045M)
    9. National Bank Financial Inc. (7, $4,039M)
    10. Industrial Alliance Securities Inc. (7, $1,017M)
    11. Mackie Research Capital Corporation (7, $9M)
    12. RBC Dominion Securities Inc. (6, $4,006M)
    13. Stifel Nicolaus Canada Inc. (6, $3,623M)

    Non-CPC/SPAC IPO Ranking (#, $total IPO value)

    1. Canaccord Genuity Corp. (17, $1,846M)
    2. BMO Nesbitt Burns Inc. (12, $4,651M)
    3. Haywood Securities Inc. (9, $20M)
    4. Scotia Capital Inc. (9, $4,349M)
    5. CIBC World Markets Inc. (8, $4,372M)
    6. Raymond James Ltd. (7, $4,053M)
    7. TD Securities Inc. (7, $4,045M)
    8. National Bank Financial Inc. (7, $4,039M)
    9. RBC Dominion Securities Inc. (6, $4,006M)
    10. Stifel Nicolaus Canada Inc. (6, $3,623M)
    11. Leede Jones Gable Inc. (6, $12M)
    12. Mackie Research Capital Corporation (6, $8M)
    13. Desjardins Securities Inc.  (5, $952M)

    2020 Top Five Canadian IPOs (Canadian and foreign exchanges)

    Three of top five Canadian IPOs were done on the NASDAQ Exchange. The Top Five are backed either by private equity or venture capital firms.

    Issuer

    Backed

    Close Date

    $ Raised (Mil)

    Exchange(s)

    Valuation* ($Mil)

    GFL Environmental Inc.

    PE

    2020-03-05

    $1,425 (US)

    TSX/NYSE: GFL

    $6,416 (US)

    Nuvei Corporation

    PE

    2020-09-22

    $805 (US)

    TSX: NVEI

    $3,390 (US)

    AbCellera Biologics Inc.

    VC

    2020-12-15

    $555 (US)

    NASDAQ: ABCL

    $5,384 (US)

    Repare Therapeutics Inc.

    VC

    2020-06-23

    $253 (US)

    NASDAD: RPTX

    $700 (US)

    Fusion Pharmaceuticals Inc.

    VC

    2020-06-30

    $213 (US)

    NASDAQ: FUSN

    $708 (US)

    Report Summary

    2020 Canadian IPO Report Summary can be downloaded from financings.ca https://www.financings.ca/reports/

    About CPE Analytics

    CPE Analytics, through financings.ca, is Canada's all public and private financing data provider. We offer comprehensive data coverage and analysis on private capital and public financings, IPOs, M&As and VC/PE fundraising. More information:  https://cpeanalytics.ca

    CPE Analytics is a division of CPE Media Inc., Canada's all financing news and data provider.

    SOURCE CPE Media Inc.

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2021/05/c5740.html

    View Full Article Hide Full Article
  27. Study will provide real-world data to evaluate the effectiveness of bamlanivimab in reducing COVID-19 hospitalizations in a high-risk population

    AbCellera (NASDAQ:ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody developed through AbCellera's collaboration with Eli Lilly and Company (Lilly), will be evaluated in a new pragmatic study in high-risk patients with COVID-19. Lilly's trial, in collaboration with the state of New Mexico and major local institutions, will collect data on the effectiveness and safety of bamlanivimab in a real-world setting that includes a diverse population and spans both rural and urban environments. As part of this study, Lilly will employ its unique mobile research units used successfully in…

    Study will provide real-world data to evaluate the effectiveness of bamlanivimab in reducing COVID-19 hospitalizations in a high-risk population

    AbCellera (NASDAQ:ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody developed through AbCellera's collaboration with Eli Lilly and Company (Lilly), will be evaluated in a new pragmatic study in high-risk patients with COVID-19. Lilly's trial, in collaboration with the state of New Mexico and major local institutions, will collect data on the effectiveness and safety of bamlanivimab in a real-world setting that includes a diverse population and spans both rural and urban environments. As part of this study, Lilly will employ its unique mobile research units used successfully in other studies. Additional details regarding the new trial can be found here.

    "By deploying on-site infusion clinics, Lilly continues to lead in finding ways to bring antibody treatments to patients," said Carl Hansen, Ph.D., CEO of AbCellera. "We applaud their continued innovation and tireless efforts in fighting the COVID-19 pandemic."

    Bamlanivimab is currently authorized in the United States and Canada for the treatment of mild to moderate COVID-19 patients who are at high risk for progressing to severe COVID-19 and/or hospitalization. Both the Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration and the interim authorization granted by Health Canada under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 are based on data from BLAZE-1, a randomized, double-blind placebo-controlled Phase 2 study in patients with recently diagnosed mild to moderate COVID-19 in the outpatient setting. Data from BLAZE-1 showed bamlanivimab reduced viral load, symptoms, and hospitalizations.

    AbCellera's COVID-19 response was based on capabilities developed over the past two years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of P3 is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen.

    About Bamlanivimab

    Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

    Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing, testing bamlanivimab alone and in combination with a second antibody. Data from the monotherapy arms of BLAZE-1 were published in the New England Journal of Medicine. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

    About AbCellera Biologics Inc.

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.

    View Full Article Hide Full Article
  28. AbCellera Biologics Inc. ("AbCellera") (NASDAQ:ABCL), a technology company that aims to become the centralized operating system for next-generation antibody discovery, today announced the closing of its initial public offering of 27,772,500 common shares at a price to the public of $20.00 per share, which includes the exercise in full of the underwriters' option to purchase 3,622,500 additional common shares. All of the common shares were offered by AbCellera. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $555.5 million. In addition, upon the closing of the offering, previously issued convertible promissory notes, with an aggregate principal…

    AbCellera Biologics Inc. ("AbCellera") (NASDAQ:ABCL), a technology company that aims to become the centralized operating system for next-generation antibody discovery, today announced the closing of its initial public offering of 27,772,500 common shares at a price to the public of $20.00 per share, which includes the exercise in full of the underwriters' option to purchase 3,622,500 additional common shares. All of the common shares were offered by AbCellera. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $555.5 million. In addition, upon the closing of the offering, previously issued convertible promissory notes, with an aggregate principal amount of approximately $90.0 million, converted into 6,093,524 common shares at a price of $17.00 per share.

    Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as joint book-running managers for the offering.

    Registration statements relating to these securities became effective on December 10, 2020. The offering was made only by means of a prospectus, copies of which may be obtained from: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at ; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at ; Berenberg Capital Markets LLC, Attention: Investment Banking, 1251 Avenue of the Americas, 53rd Floor, New York, NY 10020, or by telephone at (646) 949-9000, or by email at ; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by email at ; or BMO Capital Markets Corp. at 3 Times Square, 25th Floor, New York, NY 10036, Attention: Equity Syndicate Department, by telephone at (800) 414-3627, or by email to .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. AbCellera conducted its initial public offering in the United States and not in any Canadian jurisdiction.

    About AbCellera Biologics

    AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.

    View Full Article Hide Full Article